[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9rL9-IpkTqzmsfGiXL-VESmBCxNcHRNzLr68WjxneP0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"University of Calgary",[4],674,false,162,55,952994,65,507,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Stroke",18,{"name":18,"count":19},"Obesity",13,{"name":21,"count":22},"Cancer",12,{"name":24,"count":25},"Atrial Fibrillation",11,{"name":27,"count":28},"Depression",10,{"name":30,"count":31},"Hypertension",9,{"name":33,"count":31},"Asthma",{"name":35,"count":36},"Coronary Artery Disease",8,[38,43,48,53,58,63,68,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05775965","HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)","2025-03","Rivaroxaban 10mg",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06457191","Roflumilast and TMS Motor Plasticity","2025-08","Roflumilast",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06456424","Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection","2025-11","Phage therapy",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05442463","Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans","2025-11-30","Captopril",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04789616","The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke","2025-12","Maraviroc",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04186286","Crossover Study of Propranolol vs Ivabradine in POTS","2025-12-31","Ivabradine 4-week course",{"nctId":69,"briefTitle":70,"date":66,"intervention":71},"NCT05755737","A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11)","Ondansetron",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06814756","Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection","2026-03","phage therapy",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT05472493","Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism","2026-06-30","[18-F]CETO",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06121284","iTBS+D-Cycloserine for Youth Suicide","2026-07","D-Cycloserine",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,126,144,176,194,212,230,248,266,293,311,402,463,504,530,548,574,607,625,643,661,687,713,731,759,809,835,870,934,960,985,1011,1029,1051,1069,1090,1117,1135,1153,1173,1197,1225,1243,1266,1284,1308,1326,1349,1379,1397,1423,1441,1466,1484,1515,1542,1575,1600,1625,1643,1665,1687,1705,1730,1748,1775,1813,1841,1877,1905,1930,1948,1974,1992,2016,2043,2061,2086,2111,2134,2158,2181,2206,2224,2249,2275,2293,2320,2344,2362,2387,2411,2436,2459,2484,2518,2554,2591,2624,2650,2674,2697,2721,2739,2764,2782,2806,2830,2856,2886,2904,2922,2944,2970,2988,3018,3036,3054,3072,3090,3114,3143,3161,3186,3204,3229,3254,3282,3300,3318,3344,3362,3386,3428,3461,3494,3517,3540,3558,3576,3594,3619,3637,3662,3688,3706,3731,3754,3778,3804,3822,3847,3870,3893,3918,3936,3960,3983,4008,4032,4054,4079,4104,4122,4148,4166,4191,4209,4234,4257,4284,4308,4332,4363,4402,4424,4442,4472,4496,4520,4545,4573,4600,4625,4643,4666,4691,4716,4743,4771,4789,4812,4843,4861,4879,4904,4927],{"intervention":96,"totalTrials":97,"cells":98},"0.9% Sodium Chloride",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":124},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":122},"NCT05603741","Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers","ACTIVE_NOT_RECRUITING",[92],"2027-01","2027-06","2022-11-10",155,[120,121],"Ehlers-Danlos Syndrome","Anesthesia, Local",[96,123],"Lidocaine Injection 2%",{"trials":125,"activeCount":101},[],{"intervention":123,"totalTrials":97,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":142},{"trials":129,"activeCount":101},[],{"trials":131,"activeCount":101},[],{"trials":133,"activeCount":101},[],{"trials":135,"activeCount":101},[],{"trials":137,"activeCount":97,"soonestReadout":115},[138],{"nctId":111,"briefTitle":112,"status":113,"phases":139,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":140,"interventions":141},[92],[120,121],[96,123],{"trials":143,"activeCount":101},[],{"intervention":145,"totalTrials":97,"cells":146},"TNFa Antagonist - Infliximab",{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":174},{"trials":148,"activeCount":101},[],{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":101},[],{"trials":154,"activeCount":101},[],{"trials":156,"activeCount":97,"soonestReadout":162},[157],{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":168},"NCT05928039","PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","RECRUITING",[92],"2027-07-30","2028-12-31","2023-10-25",297,[167],"Crohn Disease",[145,169,170,171,172,173],"TNFa Antagonist - Adalimumab","Anti-IL12\u002F23 or anti-IL23 - Ustekinumab","Anti-IL12\u002F23 or anti-IL23 - Risankizumab","Anti-integrin - Vedolizumab IV","Anti-integrin - Vedolizumab IV and SC",{"trials":175,"activeCount":101},[],{"intervention":169,"totalTrials":97,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":192},{"trials":179,"activeCount":101},[],{"trials":181,"activeCount":101},[],{"trials":183,"activeCount":101},[],{"trials":185,"activeCount":101},[],{"trials":187,"activeCount":97,"soonestReadout":162},[188],{"nctId":158,"briefTitle":159,"status":160,"phases":189,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":190,"interventions":191},[92],[167],[145,169,170,171,172,173],{"trials":193,"activeCount":101},[],{"intervention":170,"totalTrials":97,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":210},{"trials":197,"activeCount":101},[],{"trials":199,"activeCount":101},[],{"trials":201,"activeCount":101},[],{"trials":203,"activeCount":101},[],{"trials":205,"activeCount":97,"soonestReadout":162},[206],{"nctId":158,"briefTitle":159,"status":160,"phases":207,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":208,"interventions":209},[92],[167],[145,169,170,171,172,173],{"trials":211,"activeCount":101},[],{"intervention":171,"totalTrials":97,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":101},[],{"trials":217,"activeCount":101},[],{"trials":219,"activeCount":101},[],{"trials":221,"activeCount":101},[],{"trials":223,"activeCount":97,"soonestReadout":162},[224],{"nctId":158,"briefTitle":159,"status":160,"phases":225,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":226,"interventions":227},[92],[167],[145,169,170,171,172,173],{"trials":229,"activeCount":101},[],{"intervention":172,"totalTrials":97,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":246},{"trials":233,"activeCount":101},[],{"trials":235,"activeCount":101},[],{"trials":237,"activeCount":101},[],{"trials":239,"activeCount":101},[],{"trials":241,"activeCount":97,"soonestReadout":162},[242],{"nctId":158,"briefTitle":159,"status":160,"phases":243,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":244,"interventions":245},[92],[167],[145,169,170,171,172,173],{"trials":247,"activeCount":101},[],{"intervention":173,"totalTrials":97,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":258,"NA":264},{"trials":251,"activeCount":101},[],{"trials":253,"activeCount":101},[],{"trials":255,"activeCount":101},[],{"trials":257,"activeCount":101},[],{"trials":259,"activeCount":97,"soonestReadout":162},[260],{"nctId":158,"briefTitle":159,"status":160,"phases":261,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":262,"interventions":263},[92],[167],[145,169,170,171,172,173],{"trials":265,"activeCount":101},[],{"intervention":267,"totalTrials":97,"cells":268},"Low Dose Naltrexone",{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":291},{"trials":270,"activeCount":101},[],{"trials":272,"activeCount":101},[],{"trials":274,"activeCount":101},[],{"trials":276,"activeCount":101},[],{"trials":278,"activeCount":97,"soonestReadout":284},[279],{"nctId":280,"briefTitle":281,"status":282,"phases":283,"primaryCompletion":284,"completion":285,"start":85,"enrollment":286,"conditions":287,"interventions":289},"NCT05363514","Low Dose Naltrexone Use in Patients With POTS","NOT_YET_RECRUITING",[92],"2029-06","2030-12",80,[288],"Postural Orthostatic Tachycardia Syndrome",[267,290],"Microcrystalline cellulose",{"trials":292,"activeCount":101},[],{"intervention":290,"totalTrials":97,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":309},{"trials":296,"activeCount":101},[],{"trials":298,"activeCount":101},[],{"trials":300,"activeCount":101},[],{"trials":302,"activeCount":101},[],{"trials":304,"activeCount":97,"soonestReadout":284},[305],{"nctId":280,"briefTitle":281,"status":282,"phases":306,"primaryCompletion":284,"completion":285,"start":85,"enrollment":286,"conditions":307,"interventions":308},[92],[288],[267,290],{"trials":310,"activeCount":101},[],{"intervention":312,"totalTrials":313,"cells":314},"Normal saline",6,{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":345,"PHASE4":366,"NA":368},{"trials":316,"activeCount":101},[],{"trials":318,"activeCount":101},[],{"trials":320,"activeCount":101},[321,334],{"nctId":322,"briefTitle":323,"status":324,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":22,"conditions":329,"interventions":331},"NCT00850005","Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain","UNKNOWN",[90],"2010-07","2010-12","2009-02",[330],"Neuropathic Pain",[332,333],"Intravenous immunoglobulin","Normal Saline",{"nctId":335,"briefTitle":336,"status":337,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":22,"conditions":341,"interventions":343},"NCT01469559","Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy","COMPLETED",[90],"2012-07","2011-08",[342],"Diabetic Peripheral Neuropathy",[344,312],"Novolin Toronto insulin",{"trials":346,"activeCount":97,"soonestReadout":351},[347],{"nctId":348,"briefTitle":349,"status":160,"phases":350,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":362},"NCT06160778","Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal Pain",[91],"2029-01","2029-12","2024-05-27",495,[356,357,358,359,360,361],"Acute Pain","Abdomen, Acute","Abdominal Pain","Appendicitis","Emergencies","Child, Only",[363,364,365,312],"Ketorolac Tromethamine","Morphine Sulfate","normal saline",{"trials":367,"activeCount":101},[],{"trials":369,"activeCount":97,"soonestReadout":374},[370,381,394],{"nctId":371,"briefTitle":372,"status":160,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":379},"NCT05765071","Treatment of Lower Leg Anterolateral Chronic Exertional Compartment Syndrome With Intra-muscular Botulinum Injections.",[93],"2028-06-30","2025-07-17",50,[378],"Chronic Exertional Compartment Syndrome",[380,312],"Botulinum toxin A",{"nctId":382,"briefTitle":383,"status":337,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":392},"NCT00896311","Intravenous (IV) Nitroglycerin for Versions in Nulliparous Women",[93],"2006-10","2008-02","2003-03",82,[390,391],"Breech Presentation","Complication of Pregnancy",[393,312],"IV Nitroglycerin",{"nctId":395,"briefTitle":396,"status":337,"phases":397,"primaryCompletion":385,"completion":386,"start":387,"enrollment":398,"conditions":399,"interventions":401},"NCT00901758","Intravenous (IV) Nitroglycerin for Versions in Multiparous Women",[93],44,[390,400],"Pregnancy Complication",[393,312],{"intervention":403,"totalTrials":404,"cells":405},"Tenecteplase",4,{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":420,"PHASE4":459,"NA":461},{"trials":407,"activeCount":101},[],{"trials":409,"activeCount":101},[],{"trials":411,"activeCount":101},[412],{"nctId":413,"briefTitle":414,"status":337,"phases":415,"primaryCompletion":416,"completion":416,"start":339,"enrollment":376,"conditions":417,"interventions":419},"NCT01654445","TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion",[90],"2014-07",[418],"Ischemic Stroke",[403],{"trials":421,"activeCount":97,"soonestReadout":426},[422,435,448],{"nctId":423,"briefTitle":424,"status":160,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":434},"NCT06320431","ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632",[91],"2030-09-30","2030-12-31","2024-09-26",4000,[431,432,433],"Acute Ischemic Stroke AIS","Stroke Acute","Stroke, Acute, Stroke Ischemic",[403],{"nctId":436,"briefTitle":437,"status":337,"phases":438,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":446},"NCT03889249","Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke",[91],"2022-04-26","2023-04-30","2019-12-10",1600,[444,445],"Stroke, Acute","Thromboses, Intracranial",[403,447],"Alteplase",{"nctId":449,"briefTitle":450,"status":337,"phases":451,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":457},"NCT02398656","A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion",[91],"2024-01-19","2024-04-10","2015-04-01",1274,[444],[403,458],"Antiplatelet treatment",{"trials":460,"activeCount":101},[],{"trials":462,"activeCount":101},[],{"intervention":464,"totalTrials":465,"cells":466},"Aspirin",2,{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":500,"NA":502},{"trials":468,"activeCount":101},[],{"trials":470,"activeCount":101},[],{"trials":472,"activeCount":101},[],{"trials":474,"activeCount":97,"soonestReadout":479},[475,488],{"nctId":476,"briefTitle":477,"status":282,"phases":478,"primaryCompletion":479,"completion":285,"start":480,"enrollment":481,"conditions":482,"interventions":486},"NCT06494878","The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity",[91],"2030-08","2025-04",8805,[483,484,464,485],"Venous Thromboembolism","Postpartum Period","Low Molecular Weight Heparin",[464,487],"Low-molecular-weight heparin",{"nctId":489,"briefTitle":490,"status":337,"phases":491,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT00109382","Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)",[90,91],"2007-02","2003-05",500,[496,15],"Transient Ischemic Attack",[464,498,499],"Clopidogrel","Simvastatin",{"trials":501,"activeCount":101},[],{"trials":503,"activeCount":101},[],{"intervention":505,"totalTrials":97,"cells":506},"ondansetron 8 mg",{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":526,"NA":528},{"trials":508,"activeCount":101},[],{"trials":510,"activeCount":101},[],{"trials":512,"activeCount":101},[],{"trials":514,"activeCount":97,"soonestReadout":519},[515],{"nctId":516,"briefTitle":517,"status":282,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT05657925","Study of Ondansetron in the Prevention of Sleep Syncope: The Nineth Prevention of Syncope Trial (POST9)",[91],"2026-12-31","2027-12-31","2024-12-01",24,[524],"Sleep Syncope",[505],{"trials":527,"activeCount":101},[],{"trials":529,"activeCount":101},[],{"intervention":487,"totalTrials":97,"cells":531},{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":538,"PHASE4":544,"NA":546},{"trials":533,"activeCount":101},[],{"trials":535,"activeCount":101},[],{"trials":537,"activeCount":101},[],{"trials":539,"activeCount":97,"soonestReadout":479},[540],{"nctId":476,"briefTitle":477,"status":282,"phases":541,"primaryCompletion":479,"completion":285,"start":480,"enrollment":481,"conditions":542,"interventions":543},[91],[483,484,464,485],[464,487],{"trials":545,"activeCount":101},[],{"trials":547,"activeCount":101},[],{"intervention":549,"totalTrials":97,"cells":550},"Multi-strain probiotics",{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":570,"NA":572},{"trials":552,"activeCount":101},[],{"trials":554,"activeCount":101},[],{"trials":556,"activeCount":101},[],{"trials":558,"activeCount":97,"soonestReadout":563},[559],{"nctId":560,"briefTitle":561,"status":282,"phases":562,"primaryCompletion":563,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":569},"NCT06810154","Multi-strain Probiotics to Prevent Necrotizing Enterocolitis in Very Preterm Infants",[91],"2027-05-30","2028-05-30","2025-06-01",2170,[568],"Necrotizing Enterocolitis (NEC)",[549],{"trials":571,"activeCount":101},[],{"trials":573,"activeCount":101},[],{"intervention":575,"totalTrials":97,"cells":576},"Voltaren Topical Gel",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":603,"NA":605},{"trials":578,"activeCount":101},[],{"trials":580,"activeCount":101},[],{"trials":582,"activeCount":101},[],{"trials":584,"activeCount":97,"soonestReadout":589},[585],{"nctId":586,"briefTitle":587,"status":160,"phases":588,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":593,"interventions":599},"NCT07145645","Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children",[91],"2027-09-30","2028-03-31","2026-04-02",60,[594,595,596,597,598],"Musculoskeletal Injury","Pediatrics","Sprain and Strain of Ankle","Sprain Knee","Strain Knee",[575,600,601,602],"Ibuprofen Oral Suspension 100 mg\u002F5mL","ORA-Blend Oral Suspension","VersaPro Cream Base for Compounding",{"trials":604,"activeCount":101},[],{"trials":606,"activeCount":101},[],{"intervention":600,"totalTrials":97,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":621,"NA":623},{"trials":610,"activeCount":101},[],{"trials":612,"activeCount":101},[],{"trials":614,"activeCount":101},[],{"trials":616,"activeCount":97,"soonestReadout":589},[617],{"nctId":586,"briefTitle":587,"status":160,"phases":618,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":619,"interventions":620},[91],[594,595,596,597,598],[575,600,601,602],{"trials":622,"activeCount":101},[],{"trials":624,"activeCount":101},[],{"intervention":601,"totalTrials":97,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":639,"NA":641},{"trials":628,"activeCount":101},[],{"trials":630,"activeCount":101},[],{"trials":632,"activeCount":101},[],{"trials":634,"activeCount":97,"soonestReadout":589},[635],{"nctId":586,"briefTitle":587,"status":160,"phases":636,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":637,"interventions":638},[91],[594,595,596,597,598],[575,600,601,602],{"trials":640,"activeCount":101},[],{"trials":642,"activeCount":101},[],{"intervention":602,"totalTrials":97,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":657,"NA":659},{"trials":646,"activeCount":101},[],{"trials":648,"activeCount":101},[],{"trials":650,"activeCount":101},[],{"trials":652,"activeCount":97,"soonestReadout":589},[653],{"nctId":586,"briefTitle":587,"status":160,"phases":654,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":655,"interventions":656},[91],[594,595,596,597,598],[575,600,601,602],{"trials":658,"activeCount":101},[],{"trials":660,"activeCount":101},[],{"intervention":662,"totalTrials":97,"cells":663},"Atomoxetine Hydrochloride",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":683,"NA":685},{"trials":665,"activeCount":101},[],{"trials":667,"activeCount":101},[],{"trials":669,"activeCount":101},[],{"trials":671,"activeCount":97,"soonestReadout":676},[672],{"nctId":673,"briefTitle":674,"status":160,"phases":675,"primaryCompletion":676,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":682},"NCT05159687","Study of Atomoxetine in the Prevention of Vasovagal Syncope",[91],"2026-09","2027-09","2022-06-01",180,[681],"Vasovagal Syncope",[662],{"trials":684,"activeCount":101},[],{"trials":686,"activeCount":101},[],{"intervention":688,"totalTrials":97,"cells":689},"Vedolizumab",{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":709,"NA":711},{"trials":691,"activeCount":101},[],{"trials":693,"activeCount":101},[],{"trials":695,"activeCount":101},[],{"trials":697,"activeCount":97,"soonestReadout":702},[698],{"nctId":699,"briefTitle":700,"status":282,"phases":701,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":708},"NCT06337695","VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer",[90,91],"2026-11-01","2026-12-01","2024-07-01",298,[21,707],"Cancer Metastatic",[688],{"trials":710,"activeCount":101},[],{"trials":712,"activeCount":101},[],{"intervention":364,"totalTrials":97,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":727,"NA":729},{"trials":716,"activeCount":101},[],{"trials":718,"activeCount":101},[],{"trials":720,"activeCount":101},[],{"trials":722,"activeCount":97,"soonestReadout":351},[723],{"nctId":348,"briefTitle":349,"status":160,"phases":724,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":725,"interventions":726},[91],[356,357,358,359,360,361],[363,364,365,312],{"trials":728,"activeCount":101},[],{"trials":730,"activeCount":101},[],{"intervention":363,"totalTrials":465,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":745,"NA":747},{"trials":734,"activeCount":101},[],{"trials":736,"activeCount":101},[],{"trials":738,"activeCount":101},[],{"trials":740,"activeCount":97,"soonestReadout":351},[741],{"nctId":348,"briefTitle":349,"status":160,"phases":742,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":743,"interventions":744},[91],[356,357,358,359,360,361],[363,364,365,312],{"trials":746,"activeCount":101},[],{"trials":748,"activeCount":101},[749],{"nctId":750,"briefTitle":751,"status":324,"phases":752,"primaryCompletion":753,"completion":753,"start":754,"enrollment":376,"conditions":755,"interventions":758},"NCT01230463","Study of Whether 15 mg Dose of Ketorolac IV is as Effective as a 30 mg Dose.",[93],"2011-09","2010-09",[756,757],"Pain","Pain, Postoperative",[363,363],{"intervention":760,"totalTrials":761,"cells":762},"Psilocybin",3,{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":778,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":764,"activeCount":101},[],{"trials":766,"activeCount":97,"soonestReadout":771},[767],{"nctId":768,"briefTitle":769,"status":160,"phases":770,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":777},"NCT06615908","Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy",[89],"2026-10-30","2027-03-30","2025-05-27",40,[776],"Persisting Symptoms After Concussion",[760],{"trials":779,"activeCount":465,"soonestReadout":796},[780,792],{"nctId":781,"briefTitle":782,"status":282,"phases":783,"primaryCompletion":784,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":791},"NCT06885996","Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence",[90],"2028-08-01","2029-08-01","2026-08-01",76,[789,790],"Post Traumatic Stress Disorder PTSD","Intimate Partner Violence (IPV)",[760],{"nctId":793,"briefTitle":794,"status":160,"phases":795,"primaryCompletion":796,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":802},"NCT05995769","Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder",[90],"2027-10-01","2024-03-20",128,[800,801],"Alcohol Use Disorder","Alcoholism",[760],{"trials":804,"activeCount":101},[],{"trials":806,"activeCount":101},[],{"trials":808,"activeCount":101},[],{"intervention":76,"totalTrials":465,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":812,"activeCount":101},[],{"trials":814,"activeCount":101},[],{"trials":816,"activeCount":465,"soonestReadout":51},[817,823],{"nctId":73,"briefTitle":74,"status":113,"phases":818,"primaryCompletion":75,"completion":75,"start":819,"enrollment":97,"conditions":820,"interventions":822},[89,90],"2025-03-26",[821],"Prosthetic Joint Infections of Hip",[76],{"nctId":49,"briefTitle":50,"status":113,"phases":824,"primaryCompletion":51,"completion":51,"start":825,"enrollment":97,"conditions":826,"interventions":828},[89,90],"2024-11-20",[821,827],"Staphylococcus Aureus Infection",[52],{"trials":830,"activeCount":101},[],{"trials":832,"activeCount":101},[],{"trials":834,"activeCount":101},[],{"intervention":71,"totalTrials":465,"cells":836},{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":851,"PHASE4":866,"NA":868},{"trials":838,"activeCount":101},[],{"trials":840,"activeCount":101},[],{"trials":842,"activeCount":97,"soonestReadout":66},[843],{"nctId":69,"briefTitle":70,"status":160,"phases":844,"primaryCompletion":66,"completion":519,"start":845,"enrollment":846,"conditions":847,"interventions":850},[90],"2023-06-01",70,[848,849],"Vasovagal Syncope (VVS)","Syncope",[71],{"trials":852,"activeCount":101},[853],{"nctId":854,"briefTitle":855,"status":337,"phases":856,"primaryCompletion":857,"completion":857,"start":858,"enrollment":376,"conditions":859,"interventions":862},"NCT03022240","Neurobiological and Cognitive Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children",[91],"2019-09","2017-01",[860,861],"Cognitive Change","Behavior",[863,864,865,71],"Propofol","Sevoflurane","Ametop",{"trials":867,"activeCount":101},[],{"trials":869,"activeCount":101},[],{"intervention":871,"totalTrials":872,"cells":873},"D-cycloserine",5,{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":887,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":875,"activeCount":101},[],{"trials":877,"activeCount":101},[878],{"nctId":879,"briefTitle":880,"status":337,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":22,"conditions":884,"interventions":886},"NCT05731323","D-Cycloserine+iTBS PK Study",[89],"2023-06-22","2022-10-12",[885],"Major Depressive Disorder",[871],{"trials":888,"activeCount":97,"soonestReadout":85},[889,900,908,919],{"nctId":890,"briefTitle":891,"status":892,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT05395494","iTBS-DCS in Fibromyalgia","TERMINATED",[90],"2025-07-31","2022-08-29",47,[898],"Fibromyalgia",[86],{"nctId":901,"briefTitle":902,"status":337,"phases":903,"primaryCompletion":904,"completion":904,"start":905,"enrollment":376,"conditions":906,"interventions":907},"NCT03937596","Adjunctive D-Cycloserine in Major Depressive Disorder",[90],"2020-12-24","2019-12-01",[885],[871],{"nctId":909,"briefTitle":910,"status":324,"phases":911,"primaryCompletion":912,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":918},"NCT05177601","iTBS-DCS in Obsessive Compulsive Disorder",[90],"2024-10","2025-10","2021-11-26",81,[917],"Obsessive-Compulsive Disorder",[871],{"nctId":83,"briefTitle":84,"status":160,"phases":920,"primaryCompletion":85,"completion":676,"start":921,"enrollment":922,"conditions":923,"interventions":927},[90],"2024-03-11",54,[924,925,926],"Suicidal Ideation","Suicide, Attempted","Depression, Anxiety",[86],{"trials":929,"activeCount":101},[],{"trials":931,"activeCount":101},[],{"trials":933,"activeCount":101},[],{"intervention":935,"totalTrials":97,"cells":936},"Microbiome-guided inhaled antibiotic prophylaxis",{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":954,"PHASE4":956,"NA":958},{"trials":938,"activeCount":101},[],{"trials":940,"activeCount":101},[],{"trials":942,"activeCount":97,"soonestReadout":947},[943],{"nctId":944,"briefTitle":945,"status":282,"phases":946,"primaryCompletion":947,"completion":948,"start":949,"enrollment":846,"conditions":950,"interventions":953},"NCT07463339","Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial",[90],"2027-04-30","2028-04-30","2026-05-01",[951,952],"Critical Illness","Mechanical Ventilation",[935],{"trials":955,"activeCount":101},[],{"trials":957,"activeCount":101},[],{"trials":959,"activeCount":101},[],{"intervention":961,"totalTrials":97,"cells":962},"Probenecid",{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":964,"activeCount":101},[],{"trials":966,"activeCount":101},[],{"trials":968,"activeCount":97,"soonestReadout":519},[969],{"nctId":970,"briefTitle":971,"status":160,"phases":972,"primaryCompletion":519,"completion":519,"start":973,"enrollment":774,"conditions":974,"interventions":978},"NCT04939623","Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal",[90],"2023-10-31",[975,976,977],"Chronic Pain","Drug Dependence of Morphine Type","Symptom, Withdrawal",[961],{"trials":980,"activeCount":101},[],{"trials":982,"activeCount":101},[],{"trials":984,"activeCount":101},[],{"intervention":986,"totalTrials":97,"cells":987},"Neuromuscular Blocking Agent - Bolus Dosing",{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":1005,"PHASE4":1007,"NA":1009},{"trials":989,"activeCount":101},[],{"trials":991,"activeCount":101},[],{"trials":993,"activeCount":97,"soonestReadout":998},[994],{"nctId":995,"briefTitle":996,"status":282,"phases":997,"primaryCompletion":998,"completion":999,"start":998,"enrollment":1000,"conditions":1001,"interventions":1003},"NCT07567768","Continuous vs Bolus Neuromuscular Blockade Regimens in Moderate to Severe Hypoxemic Respiratory Failure and ARDS (COBRA)",[90],"2027-01-01","2028-01-01",100,[1002],"ARDS (Acute Respiratory Distress Syndrome)",[986,1004],"Neuromuscular Blocking Agent - Continuous",{"trials":1006,"activeCount":101},[],{"trials":1008,"activeCount":101},[],{"trials":1010,"activeCount":101},[],{"intervention":1004,"totalTrials":97,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1014,"activeCount":101},[],{"trials":1016,"activeCount":101},[],{"trials":1018,"activeCount":97,"soonestReadout":998},[1019],{"nctId":995,"briefTitle":996,"status":282,"phases":1020,"primaryCompletion":998,"completion":999,"start":998,"enrollment":1000,"conditions":1021,"interventions":1022},[90],[1002],[986,1004],{"trials":1024,"activeCount":101},[],{"trials":1026,"activeCount":101},[],{"trials":1028,"activeCount":101},[],{"intervention":67,"totalTrials":97,"cells":1030},{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1032,"activeCount":101},[],{"trials":1034,"activeCount":101},[],{"trials":1036,"activeCount":97,"soonestReadout":66},[1037],{"nctId":64,"briefTitle":65,"status":160,"phases":1038,"primaryCompletion":66,"completion":519,"start":1039,"enrollment":1040,"conditions":1041,"interventions":1043},[90],"2021-02-01",20,[1042],"Postural Tachycardia Syndrome",[67,1044],"Propranolol 4-week course",{"trials":1046,"activeCount":101},[],{"trials":1048,"activeCount":101},[],{"trials":1050,"activeCount":101},[],{"intervention":1044,"totalTrials":97,"cells":1052},{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1054,"activeCount":101},[],{"trials":1056,"activeCount":101},[],{"trials":1058,"activeCount":97,"soonestReadout":66},[1059],{"nctId":64,"briefTitle":65,"status":160,"phases":1060,"primaryCompletion":66,"completion":519,"start":1039,"enrollment":1040,"conditions":1061,"interventions":1062},[90],[1042],[67,1044],{"trials":1064,"activeCount":101},[],{"trials":1066,"activeCount":101},[],{"trials":1068,"activeCount":101},[],{"intervention":81,"totalTrials":97,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1072,"activeCount":101},[],{"trials":1074,"activeCount":101},[],{"trials":1076,"activeCount":97,"soonestReadout":80},[1077],{"nctId":78,"briefTitle":79,"status":160,"phases":1078,"primaryCompletion":80,"completion":80,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1083},[90],"2023-01-01",30,[1082],"Primary Aldosteronism",[81],{"trials":1085,"activeCount":101},[],{"trials":1087,"activeCount":101},[],{"trials":1089,"activeCount":101},[],{"intervention":1091,"totalTrials":97,"cells":1092},"Psilocybin high-dose",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1094,"activeCount":101},[],{"trials":1096,"activeCount":101},[],{"trials":1098,"activeCount":97,"soonestReadout":1103},[1099],{"nctId":1100,"briefTitle":1101,"status":160,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":798,"conditions":1106,"interventions":1108},"NCT06768944","Subjective Experience Following Psilocybin",[90],"2027-12","2028-01","2026-05-15",[1107],"Investigating the Importance of the Subjective Psychedelic Experience",[1091,1109,1110],"Psilocybin low-dose","Risperidone 1 MG",{"trials":1112,"activeCount":101},[],{"trials":1114,"activeCount":101},[],{"trials":1116,"activeCount":101},[],{"intervention":1109,"totalTrials":97,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1120,"activeCount":101},[],{"trials":1122,"activeCount":101},[],{"trials":1124,"activeCount":97,"soonestReadout":1103},[1125],{"nctId":1100,"briefTitle":1101,"status":160,"phases":1126,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":798,"conditions":1127,"interventions":1128},[90],[1107],[1091,1109,1110],{"trials":1130,"activeCount":101},[],{"trials":1132,"activeCount":101},[],{"trials":1134,"activeCount":101},[],{"intervention":1110,"totalTrials":97,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1138,"activeCount":101},[],{"trials":1140,"activeCount":101},[],{"trials":1142,"activeCount":97,"soonestReadout":1103},[1143],{"nctId":1100,"briefTitle":1101,"status":160,"phases":1144,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":798,"conditions":1145,"interventions":1146},[90],[1107],[1091,1109,1110],{"trials":1148,"activeCount":101},[],{"trials":1150,"activeCount":101},[],{"trials":1152,"activeCount":101},[],{"intervention":62,"totalTrials":97,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1156,"activeCount":101},[],{"trials":1158,"activeCount":101},[],{"trials":1160,"activeCount":97,"soonestReadout":61},[1161],{"nctId":59,"briefTitle":60,"status":160,"phases":1162,"primaryCompletion":61,"completion":61,"start":1163,"enrollment":1164,"conditions":1165,"interventions":1166},[90],"2022-09-15",120,[15],[62],{"trials":1168,"activeCount":101},[],{"trials":1170,"activeCount":101},[],{"trials":1172,"activeCount":101},[],{"intervention":1174,"totalTrials":97,"cells":1175},"subcutaneous Teriparatide",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1191,"PHASE4":1193,"NA":1195},{"trials":1177,"activeCount":101},[],{"trials":1179,"activeCount":101},[],{"trials":1181,"activeCount":97,"soonestReadout":519},[1182],{"nctId":1183,"briefTitle":1184,"status":282,"phases":1185,"primaryCompletion":519,"completion":1186,"start":1187,"enrollment":286,"conditions":1188,"interventions":1190},"NCT06303284","Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCT",[89,90],"2027-06-01","2025-01-01",[1189],"Ankle Fractures",[1174],{"trials":1192,"activeCount":101},[],{"trials":1194,"activeCount":101},[],{"trials":1196,"activeCount":101},[],{"intervention":1198,"totalTrials":97,"cells":1199},"Alemtuzumab",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1201,"activeCount":101},[],{"trials":1203,"activeCount":101},[],{"trials":1205,"activeCount":97,"soonestReadout":1210},[1206],{"nctId":1207,"briefTitle":1208,"status":160,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":22,"conditions":1212,"interventions":1217},"NCT03214354","Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor",[90],"2028-07","2017-07-05",[1213,1214,1215,1216],"Sickle Cell Disease","Stem Cell Transplant Complications","Red Blood Cell Disorder","Pure Red Cell Aplasia",[1198,1218],"Sirolimus",{"trials":1220,"activeCount":101},[],{"trials":1222,"activeCount":101},[],{"trials":1224,"activeCount":101},[],{"intervention":1218,"totalTrials":97,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1228,"activeCount":101},[],{"trials":1230,"activeCount":101},[],{"trials":1232,"activeCount":97,"soonestReadout":1210},[1233],{"nctId":1207,"briefTitle":1208,"status":160,"phases":1234,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":22,"conditions":1235,"interventions":1236},[90],[1213,1214,1215,1216],[1198,1218],{"trials":1238,"activeCount":101},[],{"trials":1240,"activeCount":101},[],{"trials":1242,"activeCount":101},[],{"intervention":42,"totalTrials":97,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1260,"PHASE4":1262,"NA":1264},{"trials":1246,"activeCount":101},[],{"trials":1248,"activeCount":101},[],{"trials":1250,"activeCount":97,"soonestReadout":41},[1251],{"nctId":39,"briefTitle":40,"status":160,"phases":1252,"primaryCompletion":41,"completion":1253,"start":1254,"enrollment":1255,"conditions":1256,"interventions":1258},[90],"2026-03-01","2024-05-21",250,[1257],"Hip Fractures",[42,1259],"acetylsalicylic acid (ASA) 81mg Oral",{"trials":1261,"activeCount":101},[],{"trials":1263,"activeCount":101},[],{"trials":1265,"activeCount":101},[],{"intervention":1259,"totalTrials":97,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1278,"PHASE4":1280,"NA":1282},{"trials":1269,"activeCount":101},[],{"trials":1271,"activeCount":101},[],{"trials":1273,"activeCount":97,"soonestReadout":41},[1274],{"nctId":39,"briefTitle":40,"status":160,"phases":1275,"primaryCompletion":41,"completion":1253,"start":1254,"enrollment":1255,"conditions":1276,"interventions":1277},[90],[1257],[42,1259],{"trials":1279,"activeCount":101},[],{"trials":1281,"activeCount":101},[],{"trials":1283,"activeCount":101},[],{"intervention":1285,"totalTrials":97,"cells":1286},"THC",{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1288,"activeCount":101},[],{"trials":1290,"activeCount":101},[],{"trials":1292,"activeCount":97,"soonestReadout":676},[1293],{"nctId":1294,"briefTitle":1295,"status":113,"phases":1296,"primaryCompletion":676,"completion":676,"start":1297,"enrollment":1080,"conditions":1298,"interventions":1300},"NCT06261489","Cannabis (THC vs. CBD) in Multiple Sclerosis",[90],"2025-12-05",[1299],"Multiple Sclerosis",[1285,1301],"CBD",{"trials":1303,"activeCount":101},[],{"trials":1305,"activeCount":101},[],{"trials":1307,"activeCount":101},[],{"intervention":1301,"totalTrials":97,"cells":1309},{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1311,"activeCount":101},[],{"trials":1313,"activeCount":101},[],{"trials":1315,"activeCount":97,"soonestReadout":676},[1316],{"nctId":1294,"briefTitle":1295,"status":113,"phases":1317,"primaryCompletion":676,"completion":676,"start":1297,"enrollment":1080,"conditions":1318,"interventions":1319},[90],[1299],[1285,1301],{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":101},[],{"trials":1325,"activeCount":101},[],{"intervention":1327,"totalTrials":97,"cells":1328},"Five phage anti-Staphylococcus aureus bacteriophage cocktail",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1330,"activeCount":101},[],{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":97,"soonestReadout":1339},[1335],{"nctId":1336,"briefTitle":1337,"status":282,"phases":1338,"primaryCompletion":1339,"completion":1339,"start":75,"enrollment":97,"conditions":1340,"interventions":1342},"NCT07461337","Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection",[89,90],"2027-03",[821,1341],"Bacteriophage Therapy",[1327],{"trials":1344,"activeCount":101},[],{"trials":1346,"activeCount":101},[],{"trials":1348,"activeCount":101},[],{"intervention":1350,"totalTrials":97,"cells":1351},"Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep",{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1353,"activeCount":101},[],{"trials":1355,"activeCount":101},[],{"trials":1357,"activeCount":97,"soonestReadout":1362},[1358],{"nctId":1359,"briefTitle":1360,"status":160,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1079,"enrollment":22,"conditions":1363,"interventions":1371},"NCT03255408","Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia",[89,90],"2027-12-30",[1364,1365,1366,1367,15,1368,1369,1370],"Obstructive Sleep Apnea of Adult","Hypoxia, Brain","Sleep Apnea","Sleep Disorder","Blood Pressure","Endothelial Dysfunction","Oxidative Stress",[1350,1372],"Drug Lowering CBF and Intermittent Hypoxia Sleep",{"trials":1374,"activeCount":101},[],{"trials":1376,"activeCount":101},[],{"trials":1378,"activeCount":101},[],{"intervention":1372,"totalTrials":97,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1382,"activeCount":101},[],{"trials":1384,"activeCount":101},[],{"trials":1386,"activeCount":97,"soonestReadout":1362},[1387],{"nctId":1359,"briefTitle":1360,"status":160,"phases":1388,"primaryCompletion":1362,"completion":1362,"start":1079,"enrollment":22,"conditions":1389,"interventions":1390},[89,90],[1364,1365,1366,1367,15,1368,1369,1370],[1350,1372],{"trials":1392,"activeCount":101},[],{"trials":1394,"activeCount":101},[],{"trials":1396,"activeCount":101},[],{"intervention":1398,"totalTrials":97,"cells":1399},"CBD 100 mg OD",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1417,"PHASE4":1419,"NA":1421},{"trials":1401,"activeCount":101},[],{"trials":1403,"activeCount":101},[],{"trials":1405,"activeCount":97,"soonestReadout":1410},[1406],{"nctId":1407,"briefTitle":1408,"status":160,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1415},"NCT03972124","Cannabis for the Prophylactic Treatment of Migraine",[90],"2028-12","2026-04-01",72,[1414],"Chronic Migraine",[1398,1416],"CBD 200 mg OD",{"trials":1418,"activeCount":101},[],{"trials":1420,"activeCount":101},[],{"trials":1422,"activeCount":101},[],{"intervention":1416,"totalTrials":97,"cells":1424},{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1429,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1426,"activeCount":101},[],{"trials":1428,"activeCount":101},[],{"trials":1430,"activeCount":97,"soonestReadout":1410},[1431],{"nctId":1407,"briefTitle":1408,"status":160,"phases":1432,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1433,"interventions":1434},[90],[1414],[1398,1416],{"trials":1436,"activeCount":101},[],{"trials":1438,"activeCount":101},[],{"trials":1440,"activeCount":101},[],{"intervention":1442,"totalTrials":97,"cells":1443},"Budesonide MMX®",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1460,"PHASE4":1462,"NA":1464},{"trials":1445,"activeCount":101},[],{"trials":1447,"activeCount":101},[],{"trials":1449,"activeCount":97,"soonestReadout":1454},[1450],{"nctId":1451,"briefTitle":1452,"status":282,"phases":1453,"primaryCompletion":1454,"completion":519,"start":1455,"enrollment":286,"conditions":1456,"interventions":1458},"NCT05915104","Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis",[90],"2026-09-01","2024-01-01",[1457],"Microscopic Colitis",[1442,1459],"Budesonide controlled ileal release (CR)",{"trials":1461,"activeCount":101},[],{"trials":1463,"activeCount":101},[],{"trials":1465,"activeCount":101},[],{"intervention":1459,"totalTrials":97,"cells":1467},{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1478,"PHASE4":1480,"NA":1482},{"trials":1469,"activeCount":101},[],{"trials":1471,"activeCount":101},[],{"trials":1473,"activeCount":97,"soonestReadout":1454},[1474],{"nctId":1451,"briefTitle":1452,"status":282,"phases":1475,"primaryCompletion":1454,"completion":519,"start":1455,"enrollment":286,"conditions":1476,"interventions":1477},[90],[1457],[1442,1459],{"trials":1479,"activeCount":101},[],{"trials":1481,"activeCount":101},[],{"trials":1483,"activeCount":101},[],{"intervention":47,"totalTrials":465,"cells":1485},{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1513},{"trials":1487,"activeCount":101},[],{"trials":1489,"activeCount":97,"soonestReadout":46},[1490,1500],{"nctId":1491,"briefTitle":1492,"status":1493,"phases":1494,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":101,"conditions":1497,"interventions":1499},"NCT04369547","Roflumilast TMS-EEG Plasticity","WITHDRAWN",[89],"2023-09-01","2022-01",[1498],"Synaptic Plasticity",[47],{"nctId":44,"briefTitle":45,"status":113,"phases":1501,"primaryCompletion":46,"completion":1502,"start":1503,"enrollment":1040,"conditions":1504,"interventions":1506},[89],"2026-06","2024-11-06",[1505],"Other Conditions of Brain",[47],{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"trials":1512,"activeCount":101},[],{"trials":1514,"activeCount":101},[],{"intervention":1516,"totalTrials":97,"cells":1517},"AVCN319301b",{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1534,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1519,"activeCount":101},[],{"trials":1521,"activeCount":97,"soonestReadout":1526},[1522],{"nctId":1523,"briefTitle":1524,"status":282,"phases":1525,"primaryCompletion":1526,"completion":1526,"start":1527,"enrollment":522,"conditions":1528,"interventions":1533},"NCT07346690","A Study Testing the Effects of Different THC Doses on Psychological and Biological Function",[89],"2028-02-01","2026-02-01",[1529,1530,1531,1532],"Evaluate PK Profile","Evaluate PD Profile","Healthy Adults","Safety and Tolerability in Healthy Volunteers",[1516,1516,1516],{"trials":1535,"activeCount":101},[],{"trials":1537,"activeCount":101},[],{"trials":1539,"activeCount":101},[],{"trials":1541,"activeCount":101},[],{"intervention":1543,"totalTrials":465,"cells":1544},"GCAR1",{"EARLY_PHASE1":1545,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1571,"NA":1573},{"trials":1546,"activeCount":465,"soonestReadout":1561},[1547,1557],{"nctId":1548,"briefTitle":1549,"status":113,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":97,"conditions":1553,"interventions":1556},"NCT06813417","CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma",[88],"2030-01-30","2025-01-30",[1554,1555],"Sarcoma","Alveolar Soft Part Sarcoma (ASPS)",[1543],{"nctId":1558,"briefTitle":1559,"status":282,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":1562,"enrollment":97,"conditions":1563,"interventions":1564},"NCT07104682","A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma",[88],"2026-11-30","2025-08-08",[1555,1554],[1543],{"trials":1566,"activeCount":101},[],{"trials":1568,"activeCount":101},[],{"trials":1570,"activeCount":101},[],{"trials":1572,"activeCount":101},[],{"trials":1574,"activeCount":101},[],{"intervention":1576,"totalTrials":97,"cells":1577},"Guselkumab Subcutaneous",{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1584,"PHASE4":1586,"NA":1588},{"trials":1579,"activeCount":101},[],{"trials":1581,"activeCount":101},[],{"trials":1583,"activeCount":101},[],{"trials":1585,"activeCount":101},[],{"trials":1587,"activeCount":101},[],{"trials":1589,"activeCount":97,"soonestReadout":677},[1590],{"nctId":1591,"briefTitle":1592,"status":160,"phases":1593,"primaryCompletion":677,"completion":1594,"start":1595,"enrollment":1596,"conditions":1597,"interventions":1599},"NCT07246460","Ultrasound and Proteomics for Guselkumab Response Assessment in Crohn's Disease (UPGRADE).",[],"2027-11","2025-10-31",90,[1598],"Crohn's Disease of Both Small and Large Intestine",[1576],{"intervention":1601,"totalTrials":97,"cells":1602},"Phenylephrine",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1609,"PHASE4":1611,"NA":1613},{"trials":1604,"activeCount":101},[],{"trials":1606,"activeCount":101},[],{"trials":1608,"activeCount":101},[],{"trials":1610,"activeCount":101},[],{"trials":1612,"activeCount":101},[],{"trials":1614,"activeCount":97,"soonestReadout":1619},[1615],{"nctId":1616,"briefTitle":1617,"status":160,"phases":1618,"primaryCompletion":1619,"completion":427,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1623},"NCT02673996","POTS Adrenergic Ab (CIHR Aims #1&2)",[],"2029-12-31","2016-01",125,[1042],[1601,1624],"Isoproterenol",{"intervention":1624,"totalTrials":97,"cells":1626},{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1633,"PHASE4":1635,"NA":1637},{"trials":1628,"activeCount":101},[],{"trials":1630,"activeCount":101},[],{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[],{"trials":1636,"activeCount":101},[],{"trials":1638,"activeCount":97,"soonestReadout":1619},[1639],{"nctId":1616,"briefTitle":1617,"status":160,"phases":1640,"primaryCompletion":1619,"completion":427,"start":1620,"enrollment":1621,"conditions":1641,"interventions":1642},[],[1042],[1601,1624],{"intervention":1644,"totalTrials":97,"cells":1645},"Medications that modulate heart rate and blood pressure",{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1650,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1647,"activeCount":101},[],{"trials":1649,"activeCount":101},[],{"trials":1651,"activeCount":101},[],{"trials":1653,"activeCount":101},[],{"trials":1655,"activeCount":101},[],{"trials":1657,"activeCount":97,"soonestReadout":519},[1658],{"nctId":1659,"briefTitle":1660,"status":160,"phases":1661,"primaryCompletion":519,"completion":519,"start":1662,"enrollment":1080,"conditions":1663,"interventions":1664},"NCT04881318","Compression Garments in the Community With POTS",[93],"2021-05-17",[288],[1644],{"intervention":57,"totalTrials":97,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1673,"PHASE4":1675,"NA":1677},{"trials":1668,"activeCount":101},[],{"trials":1670,"activeCount":101},[],{"trials":1672,"activeCount":101},[],{"trials":1674,"activeCount":101},[],{"trials":1676,"activeCount":101},[],{"trials":1678,"activeCount":97,"soonestReadout":56},[1679],{"nctId":54,"briefTitle":55,"status":160,"phases":1680,"primaryCompletion":56,"completion":56,"start":1681,"enrollment":1682,"conditions":1683,"interventions":1685},[],"2020-11-30",200,[1684],"Hormone Therapy",[57,1686],"Iohexol",{"intervention":1686,"totalTrials":97,"cells":1688},{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1690,"activeCount":101},[],{"trials":1692,"activeCount":101},[],{"trials":1694,"activeCount":101},[],{"trials":1696,"activeCount":101},[],{"trials":1698,"activeCount":101},[],{"trials":1700,"activeCount":97,"soonestReadout":56},[1701],{"nctId":54,"briefTitle":55,"status":160,"phases":1702,"primaryCompletion":56,"completion":56,"start":1681,"enrollment":1682,"conditions":1703,"interventions":1704},[],[1684],[57,1686],{"intervention":1706,"totalTrials":97,"cells":1707},"Sequential Gas Delivery",{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1714,"PHASE4":1716,"NA":1718},{"trials":1709,"activeCount":101},[],{"trials":1711,"activeCount":101},[],{"trials":1713,"activeCount":101},[],{"trials":1715,"activeCount":101},[],{"trials":1717,"activeCount":101},[],{"trials":1719,"activeCount":97,"soonestReadout":1619},[1720],{"nctId":1721,"briefTitle":1722,"status":160,"phases":1723,"primaryCompletion":1619,"completion":1724,"start":1725,"enrollment":286,"conditions":1726,"interventions":1729},"NCT05295810","Hypercapnia in Orthostatic Hypotension",[93],"2030-05-31","2022-03-01",[1727,1728],"Orthostatic Hypotension","Neurogenic Orthostatic Hypotension",[1706],{"intervention":380,"totalTrials":97,"cells":1731},{"EARLY_PHASE1":1732,"PHASE1":1734,"PHASE2":1736,"PHASE3":1738,"PHASE4":1740,"NA":1742},{"trials":1733,"activeCount":101},[],{"trials":1735,"activeCount":101},[],{"trials":1737,"activeCount":101},[],{"trials":1739,"activeCount":101},[],{"trials":1741,"activeCount":101},[],{"trials":1743,"activeCount":97,"soonestReadout":374},[1744],{"nctId":371,"briefTitle":372,"status":160,"phases":1745,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":1746,"interventions":1747},[93],[378],[380,312],{"intervention":1749,"totalTrials":97,"cells":1750},"CMV-VST",{"EARLY_PHASE1":1751,"PHASE1":1753,"PHASE2":1755,"PHASE3":1757,"PHASE4":1759,"NA":1761},{"trials":1752,"activeCount":101},[],{"trials":1754,"activeCount":101},[],{"trials":1756,"activeCount":101},[],{"trials":1758,"activeCount":101},[],{"trials":1760,"activeCount":101},[],{"trials":1762,"activeCount":97,"soonestReadout":1767},[1763],{"nctId":1764,"briefTitle":1765,"status":113,"phases":1766,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":97,"conditions":1770,"interventions":1774},"NCT07015801","CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency",[93],"2027-04","2040-04","2025-04-15",[1771,1772,1773],"Cytomegalovirus Viremia","Cytomegalovirus Pneumonia","T-Lymphocyte Immunodeficiency",[1749],{"intervention":1776,"totalTrials":465,"cells":1777},"Saline",{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1796,"PHASE4":1798,"NA":1811},{"trials":1779,"activeCount":101},[],{"trials":1781,"activeCount":101},[],{"trials":1783,"activeCount":101},[1784],{"nctId":1785,"briefTitle":1786,"status":337,"phases":1787,"primaryCompletion":1788,"completion":1789,"start":1790,"enrollment":1791,"conditions":1792,"interventions":1794},"NCT03236324","Transversalis Fascia Plane Blocks for Analgesia Post-cesarean Delivery",[90],"2022-10-13","2022-12-11","2017-09-22",106,[1793],"Cesarean Delivery",[1776,1795],"Bupivacaine-epinephrine",{"trials":1797,"activeCount":101},[],{"trials":1799,"activeCount":101},[1800],{"nctId":1801,"briefTitle":1802,"status":324,"phases":1803,"primaryCompletion":1804,"completion":1805,"start":1806,"enrollment":774,"conditions":1807,"interventions":1809},"NCT01024075","Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes",[92],"2010-11","2011-05","2009-11",[1808],"Chronic Rhinosinusitis",[1810,1776],"Dexamethasone",{"trials":1812,"activeCount":101},[],{"intervention":1810,"totalTrials":465,"cells":1814},{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1821,"PHASE4":1833,"NA":1839},{"trials":1816,"activeCount":101},[],{"trials":1818,"activeCount":101},[],{"trials":1820,"activeCount":101},[],{"trials":1822,"activeCount":101},[1823],{"nctId":1824,"briefTitle":1825,"status":324,"phases":1826,"primaryCompletion":1827,"completion":1827,"start":1828,"enrollment":1829,"conditions":1830,"interventions":1832},"NCT02938468","Mgt of Chronic Subdural Hematoma Using Dexamethasone",[90,91],"2021-09","2016-09-17",326,[1831],"Chronic Subdural Hematoma",[1810],{"trials":1834,"activeCount":101},[1835],{"nctId":1801,"briefTitle":1802,"status":324,"phases":1836,"primaryCompletion":1804,"completion":1805,"start":1806,"enrollment":774,"conditions":1837,"interventions":1838},[92],[1808],[1810,1776],{"trials":1840,"activeCount":101},[],{"intervention":1842,"totalTrials":465,"cells":1843},"Tinzaparin sodium",{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1875},{"trials":1845,"activeCount":101},[],{"trials":1847,"activeCount":101},[],{"trials":1849,"activeCount":101},[],{"trials":1851,"activeCount":101},[],{"trials":1853,"activeCount":101},[1854,1866],{"nctId":1855,"briefTitle":1856,"status":337,"phases":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1865},"NCT00203658","Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin",[92],"2000-10","1997-04",400,[1862,1863,1864],"Thrombosis","Thromboembolism","Venous Thrombosis",[1842],{"nctId":1867,"briefTitle":1868,"status":337,"phases":1869,"completion":1870,"start":1871,"enrollment":1872,"conditions":1873,"interventions":1874},"NCT00203580","Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)",[92],"2002-03","1994-12",910,[1862,1863,1864],[1842],{"trials":1876,"activeCount":101},[],{"intervention":1878,"totalTrials":97,"cells":1879},"furosemide",{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1886,"PHASE4":1888,"NA":1903},{"trials":1881,"activeCount":101},[],{"trials":1883,"activeCount":101},[],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[],{"trials":1889,"activeCount":101},[1890],{"nctId":1891,"briefTitle":1892,"status":337,"phases":1893,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":1897,"conditions":1898,"interventions":1902},"NCT00115726","Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure",[92],"2006-02","2007-04","2000-09",198,[30,1899,1900,1901],"Hypotension","Edema","Congestive Heart Failure",[1878],{"trials":1904,"activeCount":101},[],{"intervention":1906,"totalTrials":97,"cells":1907},"Beclomethasone",{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1916,"NA":1928},{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":101},[],{"trials":1915,"activeCount":101},[],{"trials":1917,"activeCount":101},[1918],{"nctId":1919,"briefTitle":1920,"status":1493,"phases":1921,"primaryCompletion":1922,"completion":1922,"start":1923,"enrollment":101,"conditions":1924,"interventions":1926},"NCT02319564","Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children",[92],"2016-10","2016-04",[1925],"Wheeze",[1906,1927],"Beclomethasone and Salbutamol",{"trials":1929,"activeCount":101},[],{"intervention":1927,"totalTrials":97,"cells":1931},{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1938,"PHASE4":1940,"NA":1946},{"trials":1933,"activeCount":101},[],{"trials":1935,"activeCount":101},[],{"trials":1937,"activeCount":101},[],{"trials":1939,"activeCount":101},[],{"trials":1941,"activeCount":101},[1942],{"nctId":1919,"briefTitle":1920,"status":1493,"phases":1943,"primaryCompletion":1922,"completion":1922,"start":1923,"enrollment":101,"conditions":1944,"interventions":1945},[92],[1925],[1906,1927],{"trials":1947,"activeCount":101},[],{"intervention":1949,"totalTrials":97,"cells":1950},"Platelet Rich Plasma",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1972},{"trials":1952,"activeCount":101},[],{"trials":1954,"activeCount":101},[],{"trials":1956,"activeCount":101},[],{"trials":1958,"activeCount":101},[],{"trials":1960,"activeCount":101},[1961],{"nctId":1962,"briefTitle":1963,"status":337,"phases":1964,"primaryCompletion":1965,"completion":1965,"start":1966,"enrollment":1967,"conditions":1968,"interventions":1970},"NCT04743986","The Effect of Platelet Rich Plasma on Partial Thickness Rotator Cuff Tears: A Randomized Controlled Trial",[92],"2019-06-06","2015-03-13",104,[1969],"Rotator Cuff Injuries",[1949,1971],"Corticosteroid",{"trials":1973,"activeCount":101},[],{"intervention":1971,"totalTrials":97,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1984,"NA":1990},{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[],{"trials":1981,"activeCount":101},[],{"trials":1983,"activeCount":101},[],{"trials":1985,"activeCount":101},[1986],{"nctId":1962,"briefTitle":1963,"status":337,"phases":1987,"primaryCompletion":1965,"completion":1965,"start":1966,"enrollment":1967,"conditions":1988,"interventions":1989},[92],[1969],[1949,1971],{"trials":1991,"activeCount":101},[],{"intervention":1993,"totalTrials":97,"cells":1994},"Haloperidol",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2001,"PHASE4":2003,"NA":2014},{"trials":1996,"activeCount":101},[],{"trials":1998,"activeCount":101},[],{"trials":2000,"activeCount":101},[],{"trials":2002,"activeCount":101},[],{"trials":2004,"activeCount":101},[2005],{"nctId":2006,"briefTitle":2007,"status":337,"phases":2008,"primaryCompletion":2009,"completion":678,"start":2010,"enrollment":404,"conditions":2011,"interventions":2013},"NCT04176055","Treatment Strategies in CHS",[92],"2021-06-01","2020-10-13",[2012],"Cannabis Hyperemesis Syndrome",[1993],{"trials":2015,"activeCount":101},[],{"intervention":2017,"totalTrials":97,"cells":2018},"Intrathecal Morphine",{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2023,"PHASE3":2025,"PHASE4":2027,"NA":2041},{"trials":2020,"activeCount":101},[],{"trials":2022,"activeCount":101},[],{"trials":2024,"activeCount":101},[],{"trials":2026,"activeCount":101},[],{"trials":2028,"activeCount":101},[2029],{"nctId":2030,"briefTitle":2031,"status":337,"phases":2032,"primaryCompletion":2033,"completion":2034,"start":2035,"enrollment":2036,"conditions":2037,"interventions":2039},"NCT01053039","The Use of Intrathecal Morphine in the Management of Acute Pain Following Decompressive Lumbar Spinal Surgery",[92],"2014-11","2015-02","2010-01",150,[2038],"Acute Pain Following Decompressive Lumbar Spinal Surgery",[2017,2040],"Intrathecal Saline",{"trials":2042,"activeCount":101},[],{"intervention":2040,"totalTrials":97,"cells":2044},{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2049,"PHASE3":2051,"PHASE4":2053,"NA":2059},{"trials":2046,"activeCount":101},[],{"trials":2048,"activeCount":101},[],{"trials":2050,"activeCount":101},[],{"trials":2052,"activeCount":101},[],{"trials":2054,"activeCount":101},[2055],{"nctId":2030,"briefTitle":2031,"status":337,"phases":2056,"primaryCompletion":2033,"completion":2034,"start":2035,"enrollment":2036,"conditions":2057,"interventions":2058},[92],[2038],[2017,2040],{"trials":2060,"activeCount":101},[],{"intervention":2062,"totalTrials":97,"cells":2063},"Riociguat Oral Product",{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2070,"PHASE4":2072,"NA":2084},{"trials":2065,"activeCount":101},[],{"trials":2067,"activeCount":101},[],{"trials":2069,"activeCount":101},[],{"trials":2071,"activeCount":101},[],{"trials":2073,"activeCount":101},[2074],{"nctId":2075,"briefTitle":2076,"status":324,"phases":2077,"primaryCompletion":2078,"completion":2079,"start":2080,"enrollment":1040,"conditions":2081,"interventions":2083},"NCT03809156","Upfront Combination Pulmonary Arterial Hypertension Therapy",[92],"2020-12-31","2021-01-31","2016-04-26",[2082],"Pulmonary Hypertension",[2062],{"trials":2085,"activeCount":101},[],{"intervention":2087,"totalTrials":97,"cells":2088},"Vaginal progesterone",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2095,"PHASE4":2097,"NA":2109},{"trials":2090,"activeCount":101},[],{"trials":2092,"activeCount":101},[],{"trials":2094,"activeCount":101},[],{"trials":2096,"activeCount":101},[],{"trials":2098,"activeCount":101},[2099],{"nctId":2100,"briefTitle":2101,"status":892,"phases":2102,"primaryCompletion":2103,"completion":2103,"start":2104,"enrollment":2105,"conditions":2106,"interventions":2108},"NCT01286246","Randomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor",[92],"2014-10","2011-01",34,[2107],"Obstetric Labor, Premature",[2087],{"trials":2110,"activeCount":101},[],{"intervention":2112,"totalTrials":97,"cells":2113},"Amiodarone Hydrochloride",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2122,"NA":2132},{"trials":2115,"activeCount":101},[],{"trials":2117,"activeCount":101},[],{"trials":2119,"activeCount":101},[],{"trials":2121,"activeCount":101},[],{"trials":2123,"activeCount":101},[2124],{"nctId":2125,"briefTitle":2126,"status":892,"phases":2127,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":761,"conditions":2130,"interventions":2131},"NCT04594746","Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study",[92],"2026-01-20","2022-02-03",[24],[2112],{"trials":2133,"activeCount":101},[],{"intervention":2135,"totalTrials":97,"cells":2136},"Desvenlafaxine",{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2143,"PHASE4":2145,"NA":2156},{"trials":2138,"activeCount":101},[],{"trials":2140,"activeCount":101},[],{"trials":2142,"activeCount":101},[],{"trials":2144,"activeCount":101},[],{"trials":2146,"activeCount":101},[2147],{"nctId":2148,"briefTitle":2149,"status":324,"phases":2150,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":2153,"conditions":2154,"interventions":2155},"NCT02330679","Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis",[92],"2016-12","2014-12",61,[885],[2135],{"trials":2157,"activeCount":101},[],{"intervention":2159,"totalTrials":97,"cells":2160},"Tinzaparin",{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2167,"PHASE4":2169,"NA":2179},{"trials":2162,"activeCount":101},[],{"trials":2164,"activeCount":101},[],{"trials":2166,"activeCount":101},[],{"trials":2168,"activeCount":101},[],{"trials":2170,"activeCount":101},[2171],{"nctId":2172,"briefTitle":2173,"status":337,"phases":2174,"primaryCompletion":2175,"completion":1805,"start":2176,"enrollment":19,"conditions":2177,"interventions":2178},"NCT00851864","Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing",[92],"2010-10","2007-10",[483],[2159],{"trials":2180,"activeCount":101},[],{"intervention":2182,"totalTrials":97,"cells":2183},"Tolvaptan",{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2190,"PHASE4":2192,"NA":2204},{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[],{"trials":2191,"activeCount":101},[],{"trials":2193,"activeCount":101},[2194],{"nctId":2195,"briefTitle":2196,"status":892,"phases":2197,"primaryCompletion":2198,"completion":2198,"start":1922,"enrollment":31,"conditions":2199,"interventions":2202},"NCT02959411","Tolvaptan for Advanced or Refractory Heart Failure",[92],"2020-06-30",[2200,2201],"Heart Failure","Hyponatremia",[2182,2203],"Standard of care diuretic therapy",{"trials":2205,"activeCount":101},[],{"intervention":2203,"totalTrials":97,"cells":2207},{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2214,"PHASE4":2216,"NA":2222},{"trials":2209,"activeCount":101},[],{"trials":2211,"activeCount":101},[],{"trials":2213,"activeCount":101},[],{"trials":2215,"activeCount":101},[],{"trials":2217,"activeCount":101},[2218],{"nctId":2195,"briefTitle":2196,"status":892,"phases":2219,"primaryCompletion":2198,"completion":2198,"start":1922,"enrollment":31,"conditions":2220,"interventions":2221},[92],[2200,2201],[2182,2203],{"trials":2223,"activeCount":101},[],{"intervention":2225,"totalTrials":97,"cells":2226},"XIAFLEX",{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2233,"PHASE4":2235,"NA":2247},{"trials":2228,"activeCount":101},[],{"trials":2230,"activeCount":101},[],{"trials":2232,"activeCount":101},[],{"trials":2234,"activeCount":101},[],{"trials":2236,"activeCount":101},[2237],{"nctId":2238,"briefTitle":2239,"status":324,"phases":2240,"primaryCompletion":2241,"completion":2241,"start":1620,"enrollment":2242,"conditions":2243,"interventions":2246},"NCT03000114","Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease",[92],"2021-01",334,[2244,2245],"Dupuytren Contracture","Dupuytren's Disease of Finger",[2225],{"trials":2248,"activeCount":101},[],{"intervention":2250,"totalTrials":97,"cells":2251},"Real iPACK block",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2260,"NA":2273},{"trials":2253,"activeCount":101},[],{"trials":2255,"activeCount":101},[],{"trials":2257,"activeCount":101},[],{"trials":2259,"activeCount":101},[],{"trials":2261,"activeCount":101},[2262],{"nctId":2263,"briefTitle":2264,"status":892,"phases":2265,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":28,"conditions":2268,"interventions":2271},"NCT04635176","Comparing Local Anesthesia With and Without iPACK Block",[92],"2026-05-27","2022-10-30",[2269,2270,757],"Osteo Arthritis Knee","Analgesia",[2250,2272],"Sham iPACK block with 20ml normal saline",{"trials":2274,"activeCount":101},[],{"intervention":2272,"totalTrials":97,"cells":2276},{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2281,"PHASE3":2283,"PHASE4":2285,"NA":2291},{"trials":2278,"activeCount":101},[],{"trials":2280,"activeCount":101},[],{"trials":2282,"activeCount":101},[],{"trials":2284,"activeCount":101},[],{"trials":2286,"activeCount":101},[2287],{"nctId":2263,"briefTitle":2264,"status":892,"phases":2288,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":28,"conditions":2289,"interventions":2290},[92],[2269,2270,757],[2250,2272],{"trials":2292,"activeCount":101},[],{"intervention":2294,"totalTrials":97,"cells":2295},"Anti-SARS-CoV-2 mAb",{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2302,"PHASE4":2304,"NA":2318},{"trials":2297,"activeCount":101},[],{"trials":2299,"activeCount":101},[],{"trials":2301,"activeCount":101},[],{"trials":2303,"activeCount":101},[],{"trials":2305,"activeCount":101},[2306],{"nctId":2307,"briefTitle":2308,"status":892,"phases":2309,"primaryCompletion":2310,"completion":2310,"start":2311,"enrollment":2312,"conditions":2313,"interventions":2317},"NCT04748588","Treatment of Nosocomial COVID-19",[92],"2022-01-31","2021-02-12",46,[2314,2315,2316],"Covid19","Nosocomial Infection","SARS-CoV2 Infection",[2294],{"trials":2319,"activeCount":101},[],{"intervention":2321,"totalTrials":97,"cells":2322},"Oxybutynin",{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2329,"PHASE4":2331,"NA":2342},{"trials":2324,"activeCount":101},[],{"trials":2326,"activeCount":101},[],{"trials":2328,"activeCount":101},[],{"trials":2330,"activeCount":101},[],{"trials":2332,"activeCount":101},[2333],{"nctId":2334,"briefTitle":2335,"status":337,"phases":2336,"primaryCompletion":416,"completion":416,"start":2337,"enrollment":915,"conditions":2338,"interventions":2340},"NCT03877289","Efficacy of Oxybutynin in Paediatric Cystitis",[92],"2008-10",[2339],"Cystitis",[2321,2341],"Antibiotics",{"trials":2343,"activeCount":101},[],{"intervention":2341,"totalTrials":97,"cells":2345},{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2352,"PHASE4":2354,"NA":2360},{"trials":2347,"activeCount":101},[],{"trials":2349,"activeCount":101},[],{"trials":2351,"activeCount":101},[],{"trials":2353,"activeCount":101},[],{"trials":2355,"activeCount":101},[2356],{"nctId":2334,"briefTitle":2335,"status":337,"phases":2357,"primaryCompletion":416,"completion":416,"start":2337,"enrollment":915,"conditions":2358,"interventions":2359},[92],[2339],[2321,2341],{"trials":2361,"activeCount":101},[],{"intervention":2363,"totalTrials":97,"cells":2364},"fludrocortisone acetate",{"EARLY_PHASE1":2365,"PHASE1":2367,"PHASE2":2369,"PHASE3":2371,"PHASE4":2373,"NA":2385},{"trials":2366,"activeCount":101},[],{"trials":2368,"activeCount":101},[],{"trials":2370,"activeCount":101},[],{"trials":2372,"activeCount":101},[],{"trials":2374,"activeCount":101},[2375],{"nctId":2376,"briefTitle":2377,"status":337,"phases":2378,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2381,"conditions":2382,"interventions":2384},"NCT00118482","Clinical Trial for the Prevention of Vasovagal Syncope",[92],"2011-07","2005-05",213,[2383],"Syncope, Vasovagal, Neurally-Mediated",[2363],{"trials":2386,"activeCount":101},[],{"intervention":2388,"totalTrials":97,"cells":2389},"Quetiapine XR",{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2409},{"trials":2391,"activeCount":101},[],{"trials":2393,"activeCount":101},[],{"trials":2395,"activeCount":101},[],{"trials":2397,"activeCount":101},[],{"trials":2399,"activeCount":101},[2400],{"nctId":2401,"briefTitle":2402,"status":337,"phases":2403,"primaryCompletion":2404,"completion":2404,"start":2405,"enrollment":2406,"conditions":2407,"interventions":2408},"NCT02132286","Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression",[92],"2012-04","2008-12",57,[885],[2388],{"trials":2410,"activeCount":101},[],{"intervention":2412,"totalTrials":97,"cells":2413},"pegylated interferon alfa-2a ( Roche) and ribavirin",{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2420,"PHASE4":2422,"NA":2434},{"trials":2415,"activeCount":101},[],{"trials":2417,"activeCount":101},[],{"trials":2419,"activeCount":101},[],{"trials":2421,"activeCount":101},[],{"trials":2423,"activeCount":101},[2424],{"nctId":2425,"briefTitle":2426,"status":337,"phases":2427,"primaryCompletion":2428,"completion":340,"start":2429,"enrollment":2430,"conditions":2431,"interventions":2433},"NCT00203606","Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C",[92],"2009-01","2004-01",66,[2432],"Hepatitis c",[2412],{"trials":2435,"activeCount":101},[],{"intervention":2437,"totalTrials":97,"cells":2438},"Montelukast Sodium",{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2443,"PHASE3":2445,"PHASE4":2447,"NA":2457},{"trials":2440,"activeCount":101},[],{"trials":2442,"activeCount":101},[],{"trials":2444,"activeCount":101},[],{"trials":2446,"activeCount":101},[],{"trials":2448,"activeCount":101},[2449],{"nctId":2450,"briefTitle":2451,"status":892,"phases":2452,"primaryCompletion":326,"completion":326,"start":2453,"enrollment":774,"conditions":2454,"interventions":2456},"NCT00351364","Does Montelukast Have an Affect on the Function of the Artery in Patients With Heart Disease",[92],"2006-07",[35,2455],"Acute Coronary Syndrome",[2437],{"trials":2458,"activeCount":101},[],{"intervention":2460,"totalTrials":97,"cells":2461},"N-Acetyl Cysteine",{"EARLY_PHASE1":2462,"PHASE1":2464,"PHASE2":2466,"PHASE3":2468,"PHASE4":2470,"NA":2482},{"trials":2463,"activeCount":101},[],{"trials":2465,"activeCount":101},[],{"trials":2467,"activeCount":101},[],{"trials":2469,"activeCount":101},[],{"trials":2471,"activeCount":101},[2472],{"nctId":2473,"briefTitle":2474,"status":324,"phases":2475,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":592,"conditions":2479,"interventions":2481},"NCT00866866","The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms",[92],"2009-12","2010-05","2009-03",[2480],"Chronic Sinonasal Symptoms",[2460],{"trials":2483,"activeCount":101},[],{"intervention":2485,"totalTrials":465,"cells":2486},"Indomethacin",{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2503,"PHASE4":2514,"NA":2516},{"trials":2488,"activeCount":101},[],{"trials":2490,"activeCount":101},[],{"trials":2492,"activeCount":101},[2493],{"nctId":2494,"briefTitle":2495,"status":337,"phases":2496,"primaryCompletion":2497,"completion":2497,"start":2104,"enrollment":22,"conditions":2498,"interventions":2501},"NCT01280006","Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans",[89,90],"2011-12",[2499,30,2500,15],"Obstructive Sleep Apnea","Cardiovascular Diseases",[2485,2502],"Celecoxib",{"trials":2504,"activeCount":101},[2505],{"nctId":2506,"briefTitle":2507,"status":892,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":31,"conditions":2511,"interventions":2513},"NCT00750581","An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants",[90,91],"2013-01","2008-08",[2512],"Patent Ductus Arteriosus",[2485],{"trials":2515,"activeCount":101},[],{"trials":2517,"activeCount":101},[],{"intervention":2519,"totalTrials":465,"cells":2520},"Amiodarone",{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2527,"PHASE4":2550,"NA":2552},{"trials":2522,"activeCount":101},[],{"trials":2524,"activeCount":101},[],{"trials":2526,"activeCount":101},[],{"trials":2528,"activeCount":101},[2529,2540],{"nctId":2530,"briefTitle":2531,"status":324,"phases":2532,"primaryCompletion":2533,"completion":2534,"start":2535,"enrollment":376,"conditions":2536,"interventions":2538},"NCT04748991","Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients",[91],"2025-01","2025-09","2024-09",[24,2537],"Post-cardiac Surgery",[2539,2519],"Vernakalant",{"nctId":2541,"briefTitle":2542,"status":337,"phases":2543,"completion":2544,"start":2545,"enrollment":2546,"conditions":2547,"interventions":2548},"NCT00251706","Amiodarone to Prevent Post-Operative Arrhythmias",[91],"2004-09","1999-02",600,[24],[2549],"amiodarone",{"trials":2551,"activeCount":101},[],{"trials":2553,"activeCount":101},[],{"intervention":2555,"totalTrials":465,"cells":2556},"Prucalopride",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2574,"PHASE4":2587,"NA":2589},{"trials":2558,"activeCount":101},[],{"trials":2560,"activeCount":101},[],{"trials":2562,"activeCount":101},[2563],{"nctId":2564,"briefTitle":2565,"status":337,"phases":2566,"primaryCompletion":2567,"completion":2567,"start":2568,"enrollment":2569,"conditions":2570,"interventions":2573},"NCT03244553","Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study",[90],"2019-12-02","2017-10-20",28,[2571,2572],"Ineffective Esophageal Motility","Dysphagia",[2555],{"trials":2575,"activeCount":101},[2576],{"nctId":2577,"briefTitle":2578,"status":337,"phases":2579,"primaryCompletion":2580,"completion":2580,"start":2581,"enrollment":2582,"conditions":2583,"interventions":2586},"NCT02031081","Prucalopride Versus Placebo in Gastroparesis",[90,91],"2018-06","2014-03",15,[2584,2585],"Gastroparesis","Diabetes Mellitus",[2555],{"trials":2588,"activeCount":101},[],{"trials":2590,"activeCount":101},[],{"intervention":2592,"totalTrials":465,"cells":2593},"atorvastatin",{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2620,"NA":2622},{"trials":2595,"activeCount":101},[],{"trials":2597,"activeCount":101},[],{"trials":2599,"activeCount":101},[],{"trials":2601,"activeCount":101},[2602,2611],{"nctId":2603,"briefTitle":2604,"status":337,"phases":2605,"primaryCompletion":2510,"completion":2510,"start":2606,"enrollment":2607,"conditions":2608,"interventions":2610},"NCT00150722","High-Density Lipoprotein (HDL) Modulation and Endothelial Function",[91],"2005-09",75,[2609],"Atherosclerosis",[2592],{"nctId":2612,"briefTitle":2613,"status":337,"phases":2614,"primaryCompletion":2175,"completion":1804,"start":1895,"enrollment":2615,"conditions":2616,"interventions":2618},"NCT00317967","Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart",[91],22,[2617],"Hypertrophic Cardiomyopathy",[2619],"Atorvastatin",{"trials":2621,"activeCount":101},[],{"trials":2623,"activeCount":101},[],{"intervention":499,"totalTrials":465,"cells":2625},{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2640,"PHASE4":2646,"NA":2648},{"trials":2627,"activeCount":101},[],{"trials":2629,"activeCount":101},[],{"trials":2631,"activeCount":101},[2632],{"nctId":2633,"briefTitle":2634,"status":337,"phases":2635,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":774,"conditions":2638,"interventions":2639},"NCT00321802","Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins",[90],"2012-12","2006-04",[24],[499],{"trials":2641,"activeCount":101},[2642],{"nctId":489,"briefTitle":490,"status":337,"phases":2643,"completion":492,"start":493,"enrollment":494,"conditions":2644,"interventions":2645},[90,91],[496,15],[464,498,499],{"trials":2647,"activeCount":101},[],{"trials":2649,"activeCount":101},[],{"intervention":2651,"totalTrials":97,"cells":2652},"Nabilone, flexible dosing",{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2657,"PHASE3":2659,"PHASE4":2670,"NA":2672},{"trials":2654,"activeCount":101},[],{"trials":2656,"activeCount":101},[],{"trials":2658,"activeCount":101},[],{"trials":2660,"activeCount":101},[2661],{"nctId":2662,"briefTitle":2663,"status":324,"phases":2664,"primaryCompletion":2104,"completion":2665,"start":2666,"enrollment":592,"conditions":2667,"interventions":2669},"NCT01035281","Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain",[91],"2011-04","2008-01",[2668],"Diabetic Neuropathies",[2651],{"trials":2671,"activeCount":101},[],{"trials":2673,"activeCount":101},[],{"intervention":2675,"totalTrials":97,"cells":2676},"Methylprednisolone",{"EARLY_PHASE1":2677,"PHASE1":2679,"PHASE2":2681,"PHASE3":2683,"PHASE4":2693,"NA":2695},{"trials":2678,"activeCount":101},[],{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[],{"trials":2684,"activeCount":101},[2685],{"nctId":2686,"briefTitle":2687,"status":337,"phases":2688,"primaryCompletion":2689,"completion":2689,"start":2103,"enrollment":1682,"conditions":2690,"interventions":2692},"NCT01997658","Preoperative Glucocorticoid Use in Major Hepatectomy",[90,91],"2018-10-30",[2691],"Complications",[2675],{"trials":2694,"activeCount":101},[],{"trials":2696,"activeCount":101},[],{"intervention":2698,"totalTrials":97,"cells":2699},"Polyethylene Glycol-Based Lavage",{"EARLY_PHASE1":2700,"PHASE1":2702,"PHASE2":2704,"PHASE3":2706,"PHASE4":2717,"NA":2719},{"trials":2701,"activeCount":101},[],{"trials":2703,"activeCount":101},[],{"trials":2705,"activeCount":101},[],{"trials":2707,"activeCount":101},[2708],{"nctId":2709,"briefTitle":2710,"status":337,"phases":2711,"primaryCompletion":2497,"completion":2497,"start":1805,"enrollment":2712,"conditions":2713,"interventions":2715},"NCT01415687","Split Dose Pico-Salax + Bisacodyl vs. PEG Split Dose",[91],171,[2714],"Bowel Preparation for Colonoscopy",[2698,2716],"Pico-Salax (Magnesium Citrate) plus Bisacodyl",{"trials":2718,"activeCount":101},[],{"trials":2720,"activeCount":101},[],{"intervention":2716,"totalTrials":97,"cells":2722},{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2729,"PHASE4":2735,"NA":2737},{"trials":2724,"activeCount":101},[],{"trials":2726,"activeCount":101},[],{"trials":2728,"activeCount":101},[],{"trials":2730,"activeCount":101},[2731],{"nctId":2709,"briefTitle":2710,"status":337,"phases":2732,"primaryCompletion":2497,"completion":2497,"start":1805,"enrollment":2712,"conditions":2733,"interventions":2734},[91],[2714],[2698,2716],{"trials":2736,"activeCount":101},[],{"trials":2738,"activeCount":101},[],{"intervention":2740,"totalTrials":97,"cells":2741},"Apomorphine Injectable Solution",{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2748,"PHASE4":2760,"NA":2762},{"trials":2743,"activeCount":101},[],{"trials":2745,"activeCount":101},[],{"trials":2747,"activeCount":101},[],{"trials":2749,"activeCount":101},[2750],{"nctId":2751,"briefTitle":2752,"status":324,"phases":2753,"primaryCompletion":2754,"completion":2755,"start":2756,"enrollment":774,"conditions":2757,"interventions":2759},"NCT04879134","Apomorphine Effects on Pain in Parkinson's Disease",[90,91],"2023-02","2023-07","2022-02-28",[2758],"Parkinson Disease",[2740],{"trials":2761,"activeCount":101},[],{"trials":2763,"activeCount":101},[],{"intervention":2539,"totalTrials":97,"cells":2765},{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2772,"PHASE4":2778,"NA":2780},{"trials":2767,"activeCount":101},[],{"trials":2769,"activeCount":101},[],{"trials":2771,"activeCount":101},[],{"trials":2773,"activeCount":101},[2774],{"nctId":2530,"briefTitle":2531,"status":324,"phases":2775,"primaryCompletion":2533,"completion":2534,"start":2535,"enrollment":376,"conditions":2776,"interventions":2777},[91],[24,2537],[2539,2519],{"trials":2779,"activeCount":101},[],{"trials":2781,"activeCount":101},[],{"intervention":2783,"totalTrials":97,"cells":2784},"Boceprevir",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2791,"PHASE4":2802,"NA":2804},{"trials":2786,"activeCount":101},[],{"trials":2788,"activeCount":101},[],{"trials":2790,"activeCount":101},[],{"trials":2792,"activeCount":101},[2793],{"nctId":2794,"briefTitle":2795,"status":337,"phases":2796,"primaryCompletion":2152,"completion":2797,"start":2798,"enrollment":25,"conditions":2799,"interventions":2801},"NCT01585584","Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment",[91],"2015-07","2012-05",[2800],"Hepatitis C",[2783],{"trials":2803,"activeCount":101},[],{"trials":2805,"activeCount":101},[],{"intervention":2807,"totalTrials":97,"cells":2808},"Botulinum toxin type A",{"EARLY_PHASE1":2809,"PHASE1":2811,"PHASE2":2813,"PHASE3":2815,"PHASE4":2826,"NA":2828},{"trials":2810,"activeCount":101},[],{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":101},[],{"trials":2816,"activeCount":101},[2817],{"nctId":2818,"briefTitle":2819,"status":324,"phases":2820,"primaryCompletion":2821,"completion":2821,"start":2822,"enrollment":774,"conditions":2823,"interventions":2825},"NCT04277247","Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease",[90,91],"2022-12","2021-01-12",[2824,2758],"Dystonia Disorder",[2807],{"trials":2827,"activeCount":101},[],{"trials":2829,"activeCount":101},[],{"intervention":2831,"totalTrials":97,"cells":2832},"Tisseel",{"EARLY_PHASE1":2833,"PHASE1":2835,"PHASE2":2837,"PHASE3":2839,"PHASE4":2852,"NA":2854},{"trials":2834,"activeCount":101},[],{"trials":2836,"activeCount":101},[],{"trials":2838,"activeCount":101},[],{"trials":2840,"activeCount":101},[2841],{"nctId":2842,"briefTitle":2843,"status":324,"phases":2844,"primaryCompletion":2845,"completion":2846,"start":2847,"enrollment":1080,"conditions":2848,"interventions":2851},"NCT05358977","Fibrin Sealant in Eyelid Surgery",[90,91],"2023-05","2023-06","2022-05",[2849,2850],"Blepharoptosis","Ecchymosis; Eyelid",[2831],{"trials":2853,"activeCount":101},[],{"trials":2855,"activeCount":101},[],{"intervention":2857,"totalTrials":97,"cells":2858},"Lactose Placebo",{"EARLY_PHASE1":2859,"PHASE1":2861,"PHASE2":2863,"PHASE3":2865,"PHASE4":2882,"NA":2884},{"trials":2860,"activeCount":101},[],{"trials":2862,"activeCount":101},[],{"trials":2864,"activeCount":101},[],{"trials":2866,"activeCount":101},[2867],{"nctId":2868,"briefTitle":2869,"status":337,"phases":2870,"primaryCompletion":2871,"completion":2872,"start":2873,"enrollment":2874,"conditions":2875,"interventions":2879},"NCT03582176","PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2",[91],"2024-09-29","2024-12-17","2019-04-26",395,[2876,2877,2878],"Elbow Fracture","Elbow Injury","Elbow Dislocation",[2857,2880,2881],"Ketotifen Fumarate 2mg","Ketotifen Fumarate 5mg",{"trials":2883,"activeCount":101},[],{"trials":2885,"activeCount":101},[],{"intervention":2880,"totalTrials":97,"cells":2887},{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2894,"PHASE4":2900,"NA":2902},{"trials":2889,"activeCount":101},[],{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":101},[],{"trials":2895,"activeCount":101},[2896],{"nctId":2868,"briefTitle":2869,"status":337,"phases":2897,"primaryCompletion":2871,"completion":2872,"start":2873,"enrollment":2874,"conditions":2898,"interventions":2899},[91],[2876,2877,2878],[2857,2880,2881],{"trials":2901,"activeCount":101},[],{"trials":2903,"activeCount":101},[],{"intervention":2881,"totalTrials":97,"cells":2905},{"EARLY_PHASE1":2906,"PHASE1":2908,"PHASE2":2910,"PHASE3":2912,"PHASE4":2918,"NA":2920},{"trials":2907,"activeCount":101},[],{"trials":2909,"activeCount":101},[],{"trials":2911,"activeCount":101},[],{"trials":2913,"activeCount":101},[2914],{"nctId":2868,"briefTitle":2869,"status":337,"phases":2915,"primaryCompletion":2871,"completion":2872,"start":2873,"enrollment":2874,"conditions":2916,"interventions":2917},[91],[2876,2877,2878],[2857,2880,2881],{"trials":2919,"activeCount":101},[],{"trials":2921,"activeCount":101},[],{"intervention":2923,"totalTrials":97,"cells":2924},"rosiglitazone\u002Fplacebo",{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2931,"PHASE4":2940,"NA":2942},{"trials":2926,"activeCount":101},[],{"trials":2928,"activeCount":101},[],{"trials":2930,"activeCount":101},[],{"trials":2932,"activeCount":101},[2933],{"nctId":2934,"briefTitle":2935,"status":892,"phases":2936,"completion":2176,"start":2937,"enrollment":774,"conditions":2938,"interventions":2939},"NCT00203632","Glitazones and Endothelial Function (GATE)",[91],"2003-09",[2585],[2923],{"trials":2941,"activeCount":101},[],{"trials":2943,"activeCount":101},[],{"intervention":2945,"totalTrials":97,"cells":2946},"Ketorolac",{"EARLY_PHASE1":2947,"PHASE1":2949,"PHASE2":2951,"PHASE3":2953,"PHASE4":2966,"NA":2968},{"trials":2948,"activeCount":101},[],{"trials":2950,"activeCount":101},[],{"trials":2952,"activeCount":101},[],{"trials":2954,"activeCount":101},[2955],{"nctId":2956,"briefTitle":2957,"status":337,"phases":2958,"primaryCompletion":2959,"completion":2960,"start":2961,"enrollment":2615,"conditions":2962,"interventions":2964},"NCT05102591","A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents",[91],"2024-03-01","2024-08-29","2022-02-22",[2963],"Migraine Disorders",[2945,2965],"Metoclopramide",{"trials":2967,"activeCount":101},[],{"trials":2969,"activeCount":101},[],{"intervention":2965,"totalTrials":97,"cells":2971},{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2976,"PHASE3":2978,"PHASE4":2984,"NA":2986},{"trials":2973,"activeCount":101},[],{"trials":2975,"activeCount":101},[],{"trials":2977,"activeCount":101},[],{"trials":2979,"activeCount":101},[2980],{"nctId":2956,"briefTitle":2957,"status":337,"phases":2981,"primaryCompletion":2959,"completion":2960,"start":2961,"enrollment":2615,"conditions":2982,"interventions":2983},[91],[2963],[2945,2965],{"trials":2985,"activeCount":101},[],{"trials":2987,"activeCount":101},[],{"intervention":2989,"totalTrials":97,"cells":2990},"Ondansetron Oral Solution",{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":2997,"PHASE4":3014,"NA":3016},{"trials":2992,"activeCount":101},[],{"trials":2994,"activeCount":101},[],{"trials":2996,"activeCount":101},[],{"trials":2998,"activeCount":101},[2999],{"nctId":3000,"briefTitle":3001,"status":337,"phases":3002,"primaryCompletion":3003,"completion":3004,"start":3005,"enrollment":3006,"conditions":3007,"interventions":3012},"NCT03851835","Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis",[91],"2024-06-27","2024-07-06","2019-09-14",1030,[3008,3009,3010,3011],"Acute Gastroenteritis","Viral Illness","Vomiting","Diarrhea",[2989,3013],"Oral Placebo",{"trials":3015,"activeCount":101},[],{"trials":3017,"activeCount":101},[],{"intervention":3013,"totalTrials":97,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3026,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":101},[],{"trials":3023,"activeCount":101},[],{"trials":3025,"activeCount":101},[],{"trials":3027,"activeCount":101},[3028],{"nctId":3000,"briefTitle":3001,"status":337,"phases":3029,"primaryCompletion":3003,"completion":3004,"start":3005,"enrollment":3006,"conditions":3030,"interventions":3031},[91],[3008,3009,3010,3011],[2989,3013],{"trials":3033,"activeCount":101},[],{"trials":3035,"activeCount":101},[],{"intervention":863,"totalTrials":97,"cells":3037},{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3044,"PHASE4":3050,"NA":3052},{"trials":3039,"activeCount":101},[],{"trials":3041,"activeCount":101},[],{"trials":3043,"activeCount":101},[],{"trials":3045,"activeCount":101},[3046],{"nctId":854,"briefTitle":855,"status":337,"phases":3047,"primaryCompletion":857,"completion":857,"start":858,"enrollment":376,"conditions":3048,"interventions":3049},[91],[860,861],[863,864,865,71],{"trials":3051,"activeCount":101},[],{"trials":3053,"activeCount":101},[],{"intervention":864,"totalTrials":97,"cells":3055},{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3062,"PHASE4":3068,"NA":3070},{"trials":3057,"activeCount":101},[],{"trials":3059,"activeCount":101},[],{"trials":3061,"activeCount":101},[],{"trials":3063,"activeCount":101},[3064],{"nctId":854,"briefTitle":855,"status":337,"phases":3065,"primaryCompletion":857,"completion":857,"start":858,"enrollment":376,"conditions":3066,"interventions":3067},[91],[860,861],[863,864,865,71],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[],{"intervention":865,"totalTrials":97,"cells":3073},{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3080,"PHASE4":3086,"NA":3088},{"trials":3075,"activeCount":101},[],{"trials":3077,"activeCount":101},[],{"trials":3079,"activeCount":101},[],{"trials":3081,"activeCount":101},[3082],{"nctId":854,"briefTitle":855,"status":337,"phases":3083,"primaryCompletion":857,"completion":857,"start":858,"enrollment":376,"conditions":3084,"interventions":3085},[91],[860,861],[863,864,865,71],{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":101},[],{"intervention":3091,"totalTrials":97,"cells":3092},"Intranasal Oxytocin",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3110,"NA":3112},{"trials":3094,"activeCount":101},[],{"trials":3096,"activeCount":101},[],{"trials":3098,"activeCount":101},[],{"trials":3100,"activeCount":101},[3101],{"nctId":3102,"briefTitle":3103,"status":337,"phases":3104,"primaryCompletion":3105,"completion":3105,"start":3106,"enrollment":522,"conditions":3107,"interventions":3109},"NCT02888574","Evaluating the Efficacy of Intranasal Oxytocin Among Individuals With Persistent Pain",[90,91],"2018-12","2016-11",[975,3108],"Pelvic Pain",[3091],{"trials":3111,"activeCount":101},[],{"trials":3113,"activeCount":101},[],{"intervention":3115,"totalTrials":97,"cells":3116},"25% Dextrose and 1% Lidocaine",{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3121,"PHASE3":3123,"PHASE4":3139,"NA":3141},{"trials":3118,"activeCount":101},[],{"trials":3120,"activeCount":101},[],{"trials":3122,"activeCount":101},[],{"trials":3124,"activeCount":101},[3125],{"nctId":3126,"briefTitle":3127,"status":324,"phases":3128,"primaryCompletion":2035,"start":3129,"enrollment":3130,"conditions":3131,"interventions":3137},"NCT00835939","Treatment for Achilles Tendinopathy",[90,91],"2007-09",17,[3132,3133,3134,3135,3136],"Achilles Tendinopathy","Achilles Tendon Enthesopathy","Mid-Portion Achilles Tendinopathy","Insertional Achilles Tendinopathy","Non-Insertional Achilles Tendinopathy",[3115,3138],"Lidocaine",{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[],{"intervention":3138,"totalTrials":97,"cells":3144},{"EARLY_PHASE1":3145,"PHASE1":3147,"PHASE2":3149,"PHASE3":3151,"PHASE4":3157,"NA":3159},{"trials":3146,"activeCount":101},[],{"trials":3148,"activeCount":101},[],{"trials":3150,"activeCount":101},[],{"trials":3152,"activeCount":101},[3153],{"nctId":3126,"briefTitle":3127,"status":324,"phases":3154,"primaryCompletion":2035,"start":3129,"enrollment":3130,"conditions":3155,"interventions":3156},[90,91],[3132,3133,3134,3135,3136],[3115,3138],{"trials":3158,"activeCount":101},[],{"trials":3160,"activeCount":101},[],{"intervention":3162,"totalTrials":97,"cells":3163},"Minocycline 100mg",{"EARLY_PHASE1":3164,"PHASE1":3166,"PHASE2":3168,"PHASE3":3170,"PHASE4":3182,"NA":3184},{"trials":3165,"activeCount":101},[],{"trials":3167,"activeCount":101},[],{"trials":3169,"activeCount":101},[],{"trials":3171,"activeCount":101},[3172],{"nctId":3173,"briefTitle":3174,"status":892,"phases":3175,"primaryCompletion":3176,"completion":3177,"start":3178,"enrollment":31,"conditions":3179,"interventions":3181},"NCT04291456","Minocycline in MS: Confirmation of Benefit",[91],"2022-12-16","2022-12-31","2020-01-31",[1299,3180],"Clinically Isolated Syndrome",[3162],{"trials":3183,"activeCount":101},[],{"trials":3185,"activeCount":101},[],{"intervention":447,"totalTrials":97,"cells":3187},{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3192,"PHASE3":3194,"PHASE4":3200,"NA":3202},{"trials":3189,"activeCount":101},[],{"trials":3191,"activeCount":101},[],{"trials":3193,"activeCount":101},[],{"trials":3195,"activeCount":101},[3196],{"nctId":436,"briefTitle":437,"status":337,"phases":3197,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":3198,"interventions":3199},[91],[444,445],[403,447],{"trials":3201,"activeCount":101},[],{"trials":3203,"activeCount":101},[],{"intervention":3205,"totalTrials":97,"cells":3206},"Acetyl Salicylate",{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3211,"PHASE3":3213,"PHASE4":3225,"NA":3227},{"trials":3208,"activeCount":101},[],{"trials":3210,"activeCount":101},[],{"trials":3212,"activeCount":101},[],{"trials":3214,"activeCount":101},[3215],{"nctId":3216,"briefTitle":3217,"status":324,"phases":3218,"primaryCompletion":2535,"completion":3219,"start":3220,"enrollment":3221,"conditions":3222,"interventions":3224},"NCT04192955","Evaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms",[91],"2024-12","2020-07-14",440,[3223],"Unruptured Cerebral Aneurysm",[3205],{"trials":3226,"activeCount":101},[],{"trials":3228,"activeCount":101},[],{"intervention":3230,"totalTrials":97,"cells":3231},"FMT oral",{"EARLY_PHASE1":3232,"PHASE1":3234,"PHASE2":3236,"PHASE3":3238,"PHASE4":3250,"NA":3252},{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":101},[],{"trials":3237,"activeCount":101},[],{"trials":3239,"activeCount":101},[3240],{"nctId":3241,"briefTitle":3242,"status":324,"phases":3243,"primaryCompletion":3244,"completion":3245,"start":3246,"enrollment":286,"conditions":3247,"interventions":3249},"NCT04805879","The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder",[90,91],"2024-03-04","2024-12-04","2021-03-04",[27,3248],"Treatment Resistant Depression",[3230],{"trials":3251,"activeCount":101},[],{"trials":3253,"activeCount":101},[],{"intervention":3255,"totalTrials":97,"cells":3256},"2% Diltiazem ointment with 1.5% lidocaine",{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3263,"PHASE4":3278,"NA":3280},{"trials":3258,"activeCount":101},[],{"trials":3260,"activeCount":101},[],{"trials":3262,"activeCount":101},[],{"trials":3264,"activeCount":101},[3265],{"nctId":3266,"briefTitle":3267,"status":324,"phases":3268,"primaryCompletion":3269,"completion":3269,"start":3270,"enrollment":3271,"conditions":3272,"interventions":3276},"NCT04887818","Diltiazem Ointment With Lidocaine vs. Nifedipine Ointment With Lidocaine Ointment for Treatment of Chronic Anal Fissure",[90,91],"2021-12","2021-06",430,[3273,3274,3275],"Fissure in Ano","Rectal Diseases","Rectal Bleed",[3255,3277],"0.3% Nifedipine ointment with 1.5% lidocaine",{"trials":3279,"activeCount":101},[],{"trials":3281,"activeCount":101},[],{"intervention":3277,"totalTrials":97,"cells":3283},{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3290,"PHASE4":3296,"NA":3298},{"trials":3285,"activeCount":101},[],{"trials":3287,"activeCount":101},[],{"trials":3289,"activeCount":101},[],{"trials":3291,"activeCount":101},[3292],{"nctId":3266,"briefTitle":3267,"status":324,"phases":3293,"primaryCompletion":3269,"completion":3269,"start":3270,"enrollment":3271,"conditions":3294,"interventions":3295},[90,91],[3273,3274,3275],[3255,3277],{"trials":3297,"activeCount":101},[],{"trials":3299,"activeCount":101},[],{"intervention":498,"totalTrials":97,"cells":3301},{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3306,"PHASE3":3308,"PHASE4":3314,"NA":3316},{"trials":3303,"activeCount":101},[],{"trials":3305,"activeCount":101},[],{"trials":3307,"activeCount":101},[],{"trials":3309,"activeCount":101},[3310],{"nctId":489,"briefTitle":490,"status":337,"phases":3311,"completion":492,"start":493,"enrollment":494,"conditions":3312,"interventions":3313},[90,91],[496,15],[464,498,499],{"trials":3315,"activeCount":101},[],{"trials":3317,"activeCount":101},[],{"intervention":3319,"totalTrials":97,"cells":3320},"Tocilizumab",{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3327,"PHASE4":3340,"NA":3342},{"trials":3322,"activeCount":101},[],{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":101},[3329],{"nctId":3330,"briefTitle":3331,"status":324,"phases":3332,"primaryCompletion":3270,"completion":3270,"start":3333,"enrollment":1080,"conditions":3334,"interventions":3339},"NCT04423042","Tocilizumab in Coronavirus-19 Positive Patients",[91],"2020-07-30",[2314,3335,3336,3337,3338],"COVID-19","Severe Acute Respiratory Syndrome Coronavirus 2","Coronavirus","Inflammation",[3319],{"trials":3341,"activeCount":101},[],{"trials":3343,"activeCount":101},[],{"intervention":458,"totalTrials":97,"cells":3345},{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3352,"PHASE4":3358,"NA":3360},{"trials":3347,"activeCount":101},[],{"trials":3349,"activeCount":101},[],{"trials":3351,"activeCount":101},[],{"trials":3353,"activeCount":101},[3354],{"nctId":449,"briefTitle":450,"status":337,"phases":3355,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":3356,"interventions":3357},[91],[444],[403,458],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[],{"intervention":3363,"totalTrials":97,"cells":3364},"Sildenafil Citrate",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3371,"PHASE4":3382,"NA":3384},{"trials":3366,"activeCount":101},[],{"trials":3368,"activeCount":101},[],{"trials":3370,"activeCount":101},[],{"trials":3372,"activeCount":101},[3373],{"nctId":3374,"briefTitle":3375,"status":324,"phases":3376,"primaryCompletion":3377,"completion":1496,"start":3378,"enrollment":522,"conditions":3379,"interventions":3381},"NCT03356353","Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation",[91],"2021-09-30","2018-03-12",[3380],"End Stage Heart Failure",[3363],{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":101},[],{"intervention":3387,"totalTrials":761,"cells":3388},"Cycloserine",{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3411,"PHASE3":3422,"PHASE4":3424,"NA":3426},{"trials":3390,"activeCount":101},[],{"trials":3392,"activeCount":101},[3393,3402],{"nctId":3394,"briefTitle":3395,"status":337,"phases":3396,"primaryCompletion":3397,"completion":3397,"start":3398,"enrollment":22,"conditions":3399,"interventions":3401},"NCT03432689","Cycloserine rTMS Plasticity Augmentation",[89],"2018-11-07","2018-08-06",[3400],"Motor Activity",[3387],{"nctId":3403,"briefTitle":3404,"status":337,"phases":3405,"primaryCompletion":3406,"completion":3407,"start":3408,"enrollment":22,"conditions":3409,"interventions":3410},"NCT03511599","Cycloserine rTMS Plasticity Augmentation in Depression",[89],"2020-12-08","2021-04-21","2018-09-03",[885],[3387],{"trials":3412,"activeCount":101},[3413],{"nctId":3414,"briefTitle":3415,"status":337,"phases":3416,"primaryCompletion":3417,"completion":3418,"start":3419,"enrollment":1040,"conditions":3420,"interventions":3421},"NCT05081986","Repeated iTBS Cycloserine Motor Plasticity",[90],"2021-10-06","2022-02-23","2021-08-18",[3400],[3387],{"trials":3423,"activeCount":101},[],{"trials":3425,"activeCount":101},[],{"trials":3427,"activeCount":101},[],{"intervention":3429,"totalTrials":465,"cells":3430},"Domperidone",{"EARLY_PHASE1":3431,"PHASE1":3433,"PHASE2":3435,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3432,"activeCount":101},[],{"trials":3434,"activeCount":101},[],{"trials":3436,"activeCount":101},[3437,3446],{"nctId":3438,"briefTitle":3439,"status":337,"phases":3440,"primaryCompletion":3441,"completion":3441,"start":3442,"enrollment":3130,"conditions":3443,"interventions":3445},"NCT02493049","Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)",[90],"2019-02","2015-08",[3444],"Multiple Sclerosis, Relapsing-Remitting",[3429],{"nctId":3447,"briefTitle":3448,"status":337,"phases":3449,"primaryCompletion":3450,"completion":3450,"start":2034,"enrollment":3451,"conditions":3452,"interventions":3454},"NCT02308137","Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)",[90],"2020-01-03",64,[3453],"Multiple Sclerosis, Secondary Progressive",[3429],{"trials":3456,"activeCount":101},[],{"trials":3458,"activeCount":101},[],{"trials":3460,"activeCount":101},[],{"intervention":3462,"totalTrials":465,"cells":3463},"Minocycline",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3488,"PHASE4":3490,"NA":3492},{"trials":3465,"activeCount":101},[],{"trials":3467,"activeCount":101},[],{"trials":3469,"activeCount":101},[3470,3478],{"nctId":3471,"briefTitle":3472,"status":892,"phases":3473,"primaryCompletion":2497,"completion":2509,"start":3474,"enrollment":313,"conditions":3475,"interventions":3477},"NCT01073813","Neuroprotection and Repair in Optic Neuritis",[90],"2010-02",[1299,3476],"Optic Neuritis",[3462],{"nctId":3479,"briefTitle":3480,"status":337,"phases":3481,"primaryCompletion":3482,"completion":3482,"start":3483,"enrollment":3484,"conditions":3485,"interventions":3487},"NCT00559494","Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury",[89,90],"2010-08","2004-06",52,[3486],"Spinal Cord Injuries",[3462],{"trials":3489,"activeCount":101},[],{"trials":3491,"activeCount":101},[],{"trials":3493,"activeCount":101},[],{"intervention":3495,"totalTrials":97,"cells":3496},"NTx 265",{"EARLY_PHASE1":3497,"PHASE1":3499,"PHASE2":3501,"PHASE3":3511,"PHASE4":3513,"NA":3515},{"trials":3498,"activeCount":101},[],{"trials":3500,"activeCount":101},[],{"trials":3502,"activeCount":101},[3503],{"nctId":3504,"briefTitle":3505,"status":324,"phases":3506,"primaryCompletion":3507,"completion":3507,"start":1804,"enrollment":28,"conditions":3508,"interventions":3510},"NCT01239706","Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1",[90],"2012-06",[3509],"Traumatic Brain Injury",[3495],{"trials":3512,"activeCount":101},[],{"trials":3514,"activeCount":101},[],{"trials":3516,"activeCount":101},[],{"intervention":3518,"totalTrials":97,"cells":3519},"Atomoxetine",{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3534,"PHASE4":3536,"NA":3538},{"trials":3521,"activeCount":101},[],{"trials":3523,"activeCount":101},[],{"trials":3525,"activeCount":101},[3526],{"nctId":3527,"briefTitle":3528,"status":337,"phases":3529,"primaryCompletion":3530,"completion":3531,"start":2797,"enrollment":2406,"conditions":3532,"interventions":3533},"NCT02500732","Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope",[90],"2018-01","2018-03",[681],[3518],{"trials":3535,"activeCount":101},[],{"trials":3537,"activeCount":101},[],{"trials":3539,"activeCount":101},[],{"intervention":1795,"totalTrials":97,"cells":3541},{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3552,"PHASE4":3554,"NA":3556},{"trials":3543,"activeCount":101},[],{"trials":3545,"activeCount":101},[],{"trials":3547,"activeCount":101},[3548],{"nctId":1785,"briefTitle":1786,"status":337,"phases":3549,"primaryCompletion":1788,"completion":1789,"start":1790,"enrollment":1791,"conditions":3550,"interventions":3551},[90],[1793],[1776,1795],{"trials":3553,"activeCount":101},[],{"trials":3555,"activeCount":101},[],{"trials":3557,"activeCount":101},[],{"intervention":2502,"totalTrials":97,"cells":3559},{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3570,"PHASE4":3572,"NA":3574},{"trials":3561,"activeCount":101},[],{"trials":3563,"activeCount":101},[],{"trials":3565,"activeCount":101},[3566],{"nctId":2494,"briefTitle":2495,"status":337,"phases":3567,"primaryCompletion":2497,"completion":2497,"start":2104,"enrollment":22,"conditions":3568,"interventions":3569},[89,90],[2499,30,2500,15],[2485,2502],{"trials":3571,"activeCount":101},[],{"trials":3573,"activeCount":101},[],{"trials":3575,"activeCount":101},[],{"intervention":332,"totalTrials":97,"cells":3577},{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3582,"PHASE3":3588,"PHASE4":3590,"NA":3592},{"trials":3579,"activeCount":101},[],{"trials":3581,"activeCount":101},[],{"trials":3583,"activeCount":101},[3584],{"nctId":322,"briefTitle":323,"status":324,"phases":3585,"primaryCompletion":326,"completion":327,"start":328,"enrollment":22,"conditions":3586,"interventions":3587},[90],[330],[332,333],{"trials":3589,"activeCount":101},[],{"trials":3591,"activeCount":101},[],{"trials":3593,"activeCount":101},[],{"intervention":3595,"totalTrials":97,"cells":3596},"Hydroxychloroquine Pill",{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3598,"activeCount":101},[],{"trials":3600,"activeCount":101},[],{"trials":3602,"activeCount":101},[3603],{"nctId":3604,"briefTitle":3605,"status":324,"phases":3606,"primaryCompletion":1495,"completion":3607,"start":3608,"enrollment":3609,"conditions":3610,"interventions":3611},"NCT05013463","Hydroxychloroquine and Indapamide in SPMS",[90],"2024-09-01","2021-10-01",35,[3453],[3595,3612],"Indapamide Pill",{"trials":3614,"activeCount":101},[],{"trials":3616,"activeCount":101},[],{"trials":3618,"activeCount":101},[],{"intervention":3612,"totalTrials":97,"cells":3620},{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3631,"PHASE4":3633,"NA":3635},{"trials":3622,"activeCount":101},[],{"trials":3624,"activeCount":101},[],{"trials":3626,"activeCount":101},[3627],{"nctId":3604,"briefTitle":3605,"status":324,"phases":3628,"primaryCompletion":1495,"completion":3607,"start":3608,"enrollment":3609,"conditions":3629,"interventions":3630},[90],[3453],[3595,3612],{"trials":3632,"activeCount":101},[],{"trials":3634,"activeCount":101},[],{"trials":3636,"activeCount":101},[],{"intervention":3638,"totalTrials":97,"cells":3639},"rabbit antithymocyte globulin",{"EARLY_PHASE1":3640,"PHASE1":3642,"PHASE2":3644,"PHASE3":3656,"PHASE4":3658,"NA":3660},{"trials":3641,"activeCount":101},[],{"trials":3643,"activeCount":101},[],{"trials":3645,"activeCount":101},[3646],{"nctId":3647,"briefTitle":3648,"status":892,"phases":3649,"primaryCompletion":3650,"completion":3651,"start":3652,"enrollment":846,"conditions":3653,"interventions":3655},"NCT01994824","Preemptive Therapy of GVHD",[90],"2017-06-30","2021-09-27","2014-01",[3654],"Graft-vs-host Disease",[3638],{"trials":3657,"activeCount":101},[],{"trials":3659,"activeCount":101},[],{"trials":3661,"activeCount":101},[],{"intervention":3663,"totalTrials":97,"cells":3664},"acetylsalicylic acid delayed release tablets, 81mg",{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3666,"activeCount":101},[],{"trials":3668,"activeCount":101},[],{"trials":3670,"activeCount":101},[3671],{"nctId":3672,"briefTitle":3673,"status":324,"phases":3674,"primaryCompletion":3675,"completion":2755,"start":3676,"enrollment":1000,"conditions":3677,"interventions":3681},"NCT05402124","The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study",[90],"2023-03","2022-07",[3678,3679,3680],"Colorectal Cancer","Colorectal Adenoma","Colorectal Adenomatous Polyp",[3663],{"trials":3683,"activeCount":101},[],{"trials":3685,"activeCount":101},[],{"trials":3687,"activeCount":101},[],{"intervention":344,"totalTrials":97,"cells":3689},{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3700,"PHASE4":3702,"NA":3704},{"trials":3691,"activeCount":101},[],{"trials":3693,"activeCount":101},[],{"trials":3695,"activeCount":101},[3696],{"nctId":335,"briefTitle":336,"status":337,"phases":3697,"primaryCompletion":339,"completion":339,"start":340,"enrollment":22,"conditions":3698,"interventions":3699},[90],[342],[344,312],{"trials":3701,"activeCount":101},[],{"trials":3703,"activeCount":101},[],{"trials":3705,"activeCount":101},[],{"intervention":3707,"totalTrials":97,"cells":3708},"Robot Rehabilitation + tDCS",{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3725,"PHASE4":3727,"NA":3729},{"trials":3710,"activeCount":101},[],{"trials":3712,"activeCount":101},[],{"trials":3714,"activeCount":101},[3715],{"nctId":3716,"briefTitle":3717,"status":324,"phases":3718,"primaryCompletion":2078,"completion":3719,"start":3720,"enrollment":1040,"conditions":3721,"interventions":3724},"NCT04233710","Robotic Rehabilitation and Brain Stimulation for Children With Hemiparetic Cerebral Palsy",[90],"2021-12-31","2019-03-25",[3722,3723],"Hemiplegic Cerebral Palsy","Perinatal Stroke",[3707],{"trials":3726,"activeCount":101},[],{"trials":3728,"activeCount":101},[],{"trials":3730,"activeCount":101},[],{"intervention":3732,"totalTrials":97,"cells":3733},"Extended-release quetiapine fumarate",{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3748,"PHASE4":3750,"NA":3752},{"trials":3735,"activeCount":101},[],{"trials":3737,"activeCount":101},[],{"trials":3739,"activeCount":101},[3740],{"nctId":3741,"briefTitle":3742,"status":337,"phases":3743,"primaryCompletion":3744,"completion":3744,"start":2152,"enrollment":3745,"conditions":3746,"interventions":3747},"NCT02087631","Safety and Tolerability of Quetiapine in Multiple Sclerosis",[89,90],"2019-07",14,[1299],[3732],{"trials":3749,"activeCount":101},[],{"trials":3751,"activeCount":101},[],{"trials":3753,"activeCount":101},[],{"intervention":3755,"totalTrials":97,"cells":3756},"Pimozide 2mg\u002Fday",{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3772,"PHASE4":3774,"NA":3776},{"trials":3758,"activeCount":101},[],{"trials":3760,"activeCount":101},[],{"trials":3762,"activeCount":101},[3763],{"nctId":3764,"briefTitle":3765,"status":324,"phases":3766,"primaryCompletion":2078,"completion":2078,"start":3767,"enrollment":1000,"conditions":3768,"interventions":3771},"NCT03272503","A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)",[90],"2017-10-27",[3769,3770],"ALS","Amyotrophic Lateral Sclerosis",[3755],{"trials":3773,"activeCount":101},[],{"trials":3775,"activeCount":101},[],{"trials":3777,"activeCount":101},[],{"intervention":3779,"totalTrials":97,"cells":3780},"Pimozide 2 mg per day",{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3785,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3782,"activeCount":101},[],{"trials":3784,"activeCount":101},[],{"trials":3786,"activeCount":101},[3787],{"nctId":3788,"briefTitle":3789,"status":324,"phases":3790,"primaryCompletion":3791,"completion":3269,"start":3792,"enrollment":3793,"conditions":3794,"interventions":3796},"NCT02463825","A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS",[90],"2016-08","2015-04",25,[3795],"Amyotrophic Lateral Sclerosis (ALS)",[3779,3797],"Pimozide 4 mg per day",{"trials":3799,"activeCount":101},[],{"trials":3801,"activeCount":101},[],{"trials":3803,"activeCount":101},[],{"intervention":3797,"totalTrials":97,"cells":3805},{"EARLY_PHASE1":3806,"PHASE1":3808,"PHASE2":3810,"PHASE3":3816,"PHASE4":3818,"NA":3820},{"trials":3807,"activeCount":101},[],{"trials":3809,"activeCount":101},[],{"trials":3811,"activeCount":101},[3812],{"nctId":3788,"briefTitle":3789,"status":324,"phases":3813,"primaryCompletion":3791,"completion":3269,"start":3792,"enrollment":3793,"conditions":3814,"interventions":3815},[90],[3795],[3779,3797],{"trials":3817,"activeCount":101},[],{"trials":3819,"activeCount":101},[],{"trials":3821,"activeCount":101},[],{"intervention":3823,"totalTrials":97,"cells":3824},"Vorinostat 100 MG",{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3829,"PHASE3":3841,"PHASE4":3843,"NA":3845},{"trials":3826,"activeCount":101},[],{"trials":3828,"activeCount":101},[],{"trials":3830,"activeCount":101},[3831],{"nctId":3832,"briefTitle":3833,"status":324,"phases":3834,"primaryCompletion":3835,"completion":3836,"start":3837,"enrollment":22,"conditions":3838,"interventions":3840},"NCT03894826","Voronistat in Pediatric Patients With Drug Resistant Epilepsy",[90],"2020-04","2020-10","2018-12-10",[3839],"Refractory Epilepsy",[3823],{"trials":3842,"activeCount":101},[],{"trials":3844,"activeCount":101},[],{"trials":3846,"activeCount":101},[],{"intervention":3848,"totalTrials":97,"cells":3849},"MCN36",{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3854,"PHASE3":3864,"PHASE4":3866,"NA":3868},{"trials":3851,"activeCount":101},[],{"trials":3853,"activeCount":101},[],{"trials":3855,"activeCount":101},[3856],{"nctId":3857,"briefTitle":3858,"status":892,"phases":3859,"primaryCompletion":2478,"completion":2478,"start":3860,"enrollment":774,"conditions":3861,"interventions":3863},"NCT00109577","Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder",[90],"2005-04",[3862],"Bipolar Disorder",[3848],{"trials":3865,"activeCount":101},[],{"trials":3867,"activeCount":101},[],{"trials":3869,"activeCount":101},[],{"intervention":3871,"totalTrials":97,"cells":3872},"Vitamin D3",{"EARLY_PHASE1":3873,"PHASE1":3875,"PHASE2":3877,"PHASE3":3887,"PHASE4":3889,"NA":3891},{"trials":3874,"activeCount":101},[],{"trials":3876,"activeCount":101},[],{"trials":3878,"activeCount":101},[3879],{"nctId":3880,"briefTitle":3881,"status":892,"phases":3882,"primaryCompletion":3883,"completion":3883,"start":3884,"enrollment":22,"conditions":3885,"interventions":3886},"NCT03302585","High-Dose Vitamin D Induction in Optic Neuritis",[90],"2024-05-09","2017-11-23",[3476],[3871],{"trials":3888,"activeCount":101},[],{"trials":3890,"activeCount":101},[],{"trials":3892,"activeCount":101},[],{"intervention":3894,"totalTrials":97,"cells":3895},"Ibuprofen",{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3900,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3897,"activeCount":101},[],{"trials":3899,"activeCount":101},[],{"trials":3901,"activeCount":101},[3902],{"nctId":3903,"briefTitle":3904,"status":324,"phases":3905,"primaryCompletion":1187,"completion":3906,"start":1039,"enrollment":1596,"conditions":3907,"interventions":3910},"NCT03949478","Treating Postictal Symptoms Using Ibuprofen and Nifedipine",[90],"2025-03-01",[3908,3909],"Epilepsy","Epilepsies, Partial",[3894,3911],"Nifedipine",{"trials":3913,"activeCount":101},[],{"trials":3915,"activeCount":101},[],{"trials":3917,"activeCount":101},[],{"intervention":3911,"totalTrials":97,"cells":3919},{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3930,"PHASE4":3932,"NA":3934},{"trials":3921,"activeCount":101},[],{"trials":3923,"activeCount":101},[],{"trials":3925,"activeCount":101},[3926],{"nctId":3903,"briefTitle":3904,"status":324,"phases":3927,"primaryCompletion":1187,"completion":3906,"start":1039,"enrollment":1596,"conditions":3928,"interventions":3929},[90],[3908,3909],[3894,3911],{"trials":3931,"activeCount":101},[],{"trials":3933,"activeCount":101},[],{"trials":3935,"activeCount":101},[],{"intervention":3937,"totalTrials":97,"cells":3938},"Human recombinant erythropoietin",{"EARLY_PHASE1":3939,"PHASE1":3941,"PHASE2":3943,"PHASE3":3954,"PHASE4":3956,"NA":3958},{"trials":3940,"activeCount":101},[],{"trials":3942,"activeCount":101},[],{"trials":3944,"activeCount":101},[3945],{"nctId":3946,"briefTitle":3947,"status":337,"phases":3948,"completion":2380,"start":2544,"enrollment":3949,"conditions":3950,"interventions":3953},"NCT00336466","The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)",[90],32,[3951,3952],"Cardiac Surgery","Brain Injury",[3937],{"trials":3955,"activeCount":101},[],{"trials":3957,"activeCount":101},[],{"trials":3959,"activeCount":101},[],{"intervention":3961,"totalTrials":97,"cells":3962},"Lidocaine 2% Injectable Solution",{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3964,"activeCount":101},[],{"trials":3966,"activeCount":101},[],{"trials":3968,"activeCount":101},[3969],{"nctId":3970,"briefTitle":3971,"status":1493,"phases":3972,"primaryCompletion":3973,"completion":703,"start":3973,"enrollment":101,"conditions":3974,"interventions":3976},"NCT05729503","Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals",[90],"2026-05-06",[3975],"Anxiety",[3961],{"trials":3978,"activeCount":101},[],{"trials":3980,"activeCount":101},[],{"trials":3982,"activeCount":101},[],{"intervention":3984,"totalTrials":97,"cells":3985},"Tissue Plasminogen Activator",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3987,"activeCount":101},[],{"trials":3989,"activeCount":101},[],{"trials":3991,"activeCount":101},[3992],{"nctId":3993,"briefTitle":3994,"status":324,"phases":3995,"primaryCompletion":3996,"completion":2404,"start":3997,"enrollment":22,"conditions":3998,"interventions":4001},"NCT01098890","Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage",[90],"2011-10","2009-10",[3999,4000],"Aneurysmal Subarachnoid Hemorrhage","Intraventricular Hemorrhage",[3984],{"trials":4003,"activeCount":101},[],{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[],{"intervention":4009,"totalTrials":97,"cells":4010},"Frovatriptan",{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4026,"PHASE4":4028,"NA":4030},{"trials":4012,"activeCount":101},[],{"trials":4014,"activeCount":101},[],{"trials":4016,"activeCount":101},[4017],{"nctId":4018,"briefTitle":4019,"status":337,"phases":4020,"primaryCompletion":4021,"completion":4021,"start":2035,"enrollment":9,"conditions":4022,"interventions":4025},"NCT01044251","Frovatriptan as a Transitional Therapy in Medication Overuse Headache",[90],"2019-04-17",[4023,4024],"Medication Overuse Headache","Analgesic Overuse Headache",[4009],{"trials":4027,"activeCount":101},[],{"trials":4029,"activeCount":101},[],{"trials":4031,"activeCount":101},[],{"intervention":4033,"totalTrials":97,"cells":4034},"Hydroxychloroquine",{"EARLY_PHASE1":4035,"PHASE1":4037,"PHASE2":4039,"PHASE3":4048,"PHASE4":4050,"NA":4052},{"trials":4036,"activeCount":101},[],{"trials":4038,"activeCount":101},[],{"trials":4040,"activeCount":101},[4041],{"nctId":4042,"briefTitle":4043,"status":337,"phases":4044,"primaryCompletion":3270,"completion":3270,"start":3106,"enrollment":3609,"conditions":4045,"interventions":4047},"NCT02913157","Hydroxychloroquine in Primary Progressive Multiple Sclerosis",[90],[4046],"Multiple Sclerosis, Primary Progressive",[4033],{"trials":4049,"activeCount":101},[],{"trials":4051,"activeCount":101},[],{"trials":4053,"activeCount":101},[],{"intervention":4055,"totalTrials":97,"cells":4056},"Ketotifen",{"EARLY_PHASE1":4057,"PHASE1":4059,"PHASE2":4061,"PHASE3":4073,"PHASE4":4075,"NA":4077},{"trials":4058,"activeCount":101},[],{"trials":4060,"activeCount":101},[],{"trials":4062,"activeCount":101},[4063],{"nctId":4064,"briefTitle":4065,"status":337,"phases":4066,"primaryCompletion":4067,"completion":4067,"start":4068,"enrollment":4069,"conditions":4070,"interventions":4072},"NCT01902017","Investigations of Mechanisms and Treatment in Post-traumatic Joint Contractures",[90],"2017-08","2013-06",152,[4071],"Joint Contractures",[4055],{"trials":4074,"activeCount":101},[],{"trials":4076,"activeCount":101},[],{"trials":4078,"activeCount":101},[],{"intervention":4080,"totalTrials":97,"cells":4081},"IN insulin",{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4086,"PHASE3":4098,"PHASE4":4100,"NA":4102},{"trials":4083,"activeCount":101},[],{"trials":4085,"activeCount":101},[],{"trials":4087,"activeCount":101},[4088],{"nctId":4089,"briefTitle":4090,"status":892,"phases":4091,"primaryCompletion":4092,"completion":4092,"start":4093,"enrollment":404,"conditions":4094,"interventions":4096},"NCT03277222","Intranasal Treatment of HIV-associated Neurocognitive Disorders",[90],"2019-04-21","2018-11-01",[4095],"HIV Associated Neurocognitive Disorder (HAND)",[4080,4097],"Sterile Saline placebo",{"trials":4099,"activeCount":101},[],{"trials":4101,"activeCount":101},[],{"trials":4103,"activeCount":101},[],{"intervention":4097,"totalTrials":97,"cells":4105},{"EARLY_PHASE1":4106,"PHASE1":4108,"PHASE2":4110,"PHASE3":4116,"PHASE4":4118,"NA":4120},{"trials":4107,"activeCount":101},[],{"trials":4109,"activeCount":101},[],{"trials":4111,"activeCount":101},[4112],{"nctId":4089,"briefTitle":4090,"status":892,"phases":4113,"primaryCompletion":4092,"completion":4092,"start":4093,"enrollment":404,"conditions":4114,"interventions":4115},[90],[4095],[4080,4097],{"trials":4117,"activeCount":101},[],{"trials":4119,"activeCount":101},[],{"trials":4121,"activeCount":101},[],{"intervention":4123,"totalTrials":97,"cells":4124},"Autologous Platelet Rich Plasma",{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4140,"PHASE3":4142,"PHASE4":4144,"NA":4146},{"trials":4126,"activeCount":101},[],{"trials":4128,"activeCount":101},[4129],{"nctId":4130,"briefTitle":4131,"status":337,"phases":4132,"primaryCompletion":4133,"completion":4133,"start":4134,"enrollment":3609,"conditions":4135,"interventions":4138},"NCT04051203","Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia",[89],"2023-12-01","2019-02-01",[4136,4137],"Occipital Neuralgia","Headache",[4123,4139],"Depo-Medrol and lidocaine",{"trials":4141,"activeCount":101},[],{"trials":4143,"activeCount":101},[],{"trials":4145,"activeCount":101},[],{"trials":4147,"activeCount":101},[],{"intervention":4139,"totalTrials":97,"cells":4149},{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4158,"PHASE3":4160,"PHASE4":4162,"NA":4164},{"trials":4151,"activeCount":101},[],{"trials":4153,"activeCount":101},[4154],{"nctId":4130,"briefTitle":4131,"status":337,"phases":4155,"primaryCompletion":4133,"completion":4133,"start":4134,"enrollment":3609,"conditions":4156,"interventions":4157},[89],[4136,4137],[4123,4139],{"trials":4159,"activeCount":101},[],{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[],{"trials":4165,"activeCount":101},[],{"intervention":4167,"totalTrials":97,"cells":4168},"D5-0.9%NS",{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4183,"PHASE3":4185,"PHASE4":4187,"NA":4189},{"trials":4170,"activeCount":101},[],{"trials":4172,"activeCount":101},[4173],{"nctId":4174,"briefTitle":4175,"status":1493,"phases":4176,"primaryCompletion":4177,"completion":4177,"start":4178,"enrollment":101,"conditions":4179,"interventions":4181},"NCT03275792","Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion",[89],"2021-04","2020-05",[4180],"Hemolytic-Uremic Syndrome",[4167,4182],"Routine home oral rehydration",{"trials":4184,"activeCount":101},[],{"trials":4186,"activeCount":101},[],{"trials":4188,"activeCount":101},[],{"trials":4190,"activeCount":101},[],{"intervention":4182,"totalTrials":97,"cells":4192},{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4201,"PHASE3":4203,"PHASE4":4205,"NA":4207},{"trials":4194,"activeCount":101},[],{"trials":4196,"activeCount":101},[4197],{"nctId":4174,"briefTitle":4175,"status":1493,"phases":4198,"primaryCompletion":4177,"completion":4177,"start":4178,"enrollment":101,"conditions":4199,"interventions":4200},[89],[4180],[4167,4182],{"trials":4202,"activeCount":101},[],{"trials":4204,"activeCount":101},[],{"trials":4206,"activeCount":101},[],{"trials":4208,"activeCount":101},[],{"intervention":4210,"totalTrials":97,"cells":4211},"Intranasal Ketamine",{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4226,"PHASE3":4228,"PHASE4":4230,"NA":4232},{"trials":4213,"activeCount":101},[],{"trials":4215,"activeCount":101},[4216],{"nctId":4217,"briefTitle":4218,"status":337,"phases":4219,"primaryCompletion":4220,"completion":4221,"start":4222,"enrollment":1080,"conditions":4223,"interventions":4225},"NCT02033434","Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study",[89],"2016-05-15","2017-09-01","2014-03-01",[756,4224],"Traumatic Limb Injury",[4210],{"trials":4227,"activeCount":101},[],{"trials":4229,"activeCount":101},[],{"trials":4231,"activeCount":101},[],{"trials":4233,"activeCount":101},[],{"intervention":4235,"totalTrials":97,"cells":4236},"Naltrexone",{"EARLY_PHASE1":4237,"PHASE1":4239,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4238,"activeCount":101},[],{"trials":4240,"activeCount":101},[4241],{"nctId":4242,"briefTitle":4243,"status":337,"phases":4244,"primaryCompletion":4245,"completion":4245,"start":1923,"enrollment":3609,"conditions":4246,"interventions":4248},"NCT02537197","The Effect of Regular Naltrexone Dosing on Disordered Gamblers",[89],"2022-05-26",[4247],"Gambling",[4235],{"trials":4250,"activeCount":101},[],{"trials":4252,"activeCount":101},[],{"trials":4254,"activeCount":101},[],{"trials":4256,"activeCount":101},[],{"intervention":4258,"totalTrials":97,"cells":4259},"Growth Hormone",{"EARLY_PHASE1":4260,"PHASE1":4274,"PHASE2":4276,"PHASE3":4278,"PHASE4":4280,"NA":4282},{"trials":4261,"activeCount":101},[4262],{"nctId":4263,"briefTitle":4264,"status":324,"phases":4265,"primaryCompletion":4266,"completion":4267,"start":2754,"enrollment":1040,"conditions":4268,"interventions":4273},"NCT05660356","Growth Hormone Deficiency in Mild Traumatic Brain Injury",[88],"2024-02","2025-02",[4269,4270,4271,4272],"Growth Hormone Treatment","Growth Hormone Deficiency","Concussion, Mild","Concussion Post Syndrome",[4258],{"trials":4275,"activeCount":101},[],{"trials":4277,"activeCount":101},[],{"trials":4279,"activeCount":101},[],{"trials":4281,"activeCount":101},[],{"trials":4283,"activeCount":101},[],{"intervention":4285,"totalTrials":97,"cells":4286},"Aspirin 81 mg",{"EARLY_PHASE1":4287,"PHASE1":4298,"PHASE2":4300,"PHASE3":4302,"PHASE4":4304,"NA":4306},{"trials":4288,"activeCount":101},[4289],{"nctId":4290,"briefTitle":4291,"status":337,"phases":4292,"primaryCompletion":4293,"completion":4293,"start":4294,"enrollment":4295,"conditions":4296,"interventions":4297},"NCT04153760","Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity",[88],"2023-09-05","2020-10-07",257,[483,484,464],[4285],{"trials":4299,"activeCount":101},[],{"trials":4301,"activeCount":101},[],{"trials":4303,"activeCount":101},[],{"trials":4305,"activeCount":101},[],{"trials":4307,"activeCount":101},[],{"intervention":4309,"totalTrials":97,"cells":4310},"adenosine",{"EARLY_PHASE1":4311,"PHASE1":4322,"PHASE2":4324,"PHASE3":4326,"PHASE4":4328,"NA":4330},{"trials":4312,"activeCount":101},[4313],{"nctId":4314,"briefTitle":4315,"status":337,"phases":4316,"primaryCompletion":753,"completion":753,"start":4317,"enrollment":1000,"conditions":4318,"interventions":4321},"NCT00693758","Assessment of Oxygen Changes in the Heart With Cardio-vascular Magnetic Resonance Imaging",[88],"2006-01",[4319,4320],"Vascular Diseases","Myocardial Ischemia",[4309],{"trials":4323,"activeCount":101},[],{"trials":4325,"activeCount":101},[],{"trials":4327,"activeCount":101},[],{"trials":4329,"activeCount":101},[],{"trials":4331,"activeCount":101},[],{"intervention":4333,"totalTrials":465,"cells":4334},"Metoprolol",{"EARLY_PHASE1":4335,"PHASE1":4337,"PHASE2":4339,"PHASE3":4341,"PHASE4":4343,"NA":4352},{"trials":4336,"activeCount":101},[],{"trials":4338,"activeCount":101},[],{"trials":4340,"activeCount":101},[],{"trials":4342,"activeCount":101},[],{"trials":4344,"activeCount":101},[4345],{"nctId":4346,"briefTitle":4347,"status":324,"phases":4348,"primaryCompletion":4349,"completion":61,"start":2103,"enrollment":3484,"conditions":4350,"interventions":4351},"NCT02123056","Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects",[92],"2021-03",[681],[4333],{"trials":4353,"activeCount":101},[4354],{"nctId":4355,"briefTitle":4356,"status":324,"phases":4357,"primaryCompletion":4358,"completion":4358,"start":2798,"enrollment":4359,"conditions":4360,"interventions":4361},"NCT01608893","Carvedilol for Prevention of Paroxysmal Atrial Fibrillation",[93],"2025-06",300,[24],[4362,4333],"Carvedilol",{"intervention":4364,"totalTrials":465,"cells":4365},"Zoledronic acid",{"EARLY_PHASE1":4366,"PHASE1":4368,"PHASE2":4382,"PHASE3":4384,"PHASE4":4386,"NA":4388},{"trials":4367,"activeCount":101},[],{"trials":4369,"activeCount":101},[4370],{"nctId":4371,"briefTitle":4372,"status":892,"phases":4373,"primaryCompletion":4374,"completion":4374,"start":4375,"enrollment":404,"conditions":4376,"interventions":4380},"NCT05204836","Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury",[89],"2025-07-03","2023-05-16",[4377,4378,4379,2269],"Anterior Cruciate Ligament Tear","Anterior Cruciate Ligament Rupture","Anterior Cruciate Ligament Injuries",[4381],"Zoledronic Acid",{"trials":4383,"activeCount":101},[],{"trials":4385,"activeCount":101},[],{"trials":4387,"activeCount":101},[],{"trials":4389,"activeCount":101},[4390],{"nctId":4391,"briefTitle":4392,"status":324,"phases":4393,"primaryCompletion":704,"completion":4394,"start":4395,"enrollment":1040,"conditions":4396,"interventions":4401},"NCT05405894","Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation",[],"2025-07-01","2022-09-01",[4397,4398,4399,4400],"Osteoporosis","Osteoporosis, Postmenopausal","Osteopenia","Bone Loss",[4364],{"intervention":393,"totalTrials":465,"cells":4403},{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4408,"PHASE3":4410,"PHASE4":4412,"NA":4414},{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":101},[],{"trials":4409,"activeCount":101},[],{"trials":4411,"activeCount":101},[],{"trials":4413,"activeCount":101},[],{"trials":4415,"activeCount":101},[4416,4420],{"nctId":382,"briefTitle":383,"status":337,"phases":4417,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":4418,"interventions":4419},[93],[390,391],[393,312],{"nctId":395,"briefTitle":396,"status":337,"phases":4421,"primaryCompletion":385,"completion":386,"start":387,"enrollment":398,"conditions":4422,"interventions":4423},[93],[390,400],[393,312],{"intervention":4362,"totalTrials":97,"cells":4425},{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4430,"PHASE3":4432,"PHASE4":4434,"NA":4436},{"trials":4427,"activeCount":101},[],{"trials":4429,"activeCount":101},[],{"trials":4431,"activeCount":101},[],{"trials":4433,"activeCount":101},[],{"trials":4435,"activeCount":101},[],{"trials":4437,"activeCount":101},[4438],{"nctId":4355,"briefTitle":4356,"status":324,"phases":4439,"primaryCompletion":4358,"completion":4358,"start":2798,"enrollment":4359,"conditions":4440,"interventions":4441},[93],[24],[4362,4333],{"intervention":4443,"totalTrials":97,"cells":4444},"Subchondroplasty",{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4449,"PHASE3":4451,"PHASE4":4453,"NA":4455},{"trials":4446,"activeCount":101},[],{"trials":4448,"activeCount":101},[],{"trials":4450,"activeCount":101},[],{"trials":4452,"activeCount":101},[],{"trials":4454,"activeCount":101},[],{"trials":4456,"activeCount":101},[4457],{"nctId":4458,"briefTitle":4459,"status":324,"phases":4460,"primaryCompletion":4461,"completion":4462,"start":4463,"enrollment":16,"conditions":4464,"interventions":4471},"NCT03699046","Evaluating the Effectiveness of Subchondroplasty for Treating Bone Marrow Lesions of the Knee",[93],"2021-03-31","2021-05-01","2018-10-18",[4465,4466,4467,4468,4469,4470],"Osteoarthritis, Knee","Arthroscopy","Musculoskeletal Disease","Bone Marrow Edema","Subchondral Bone Edema","Knee Osteoarthritis",[4443],{"intervention":4473,"totalTrials":97,"cells":4474},"HRV-39",{"EARLY_PHASE1":4475,"PHASE1":4477,"PHASE2":4479,"PHASE3":4481,"PHASE4":4483,"NA":4485},{"trials":4476,"activeCount":101},[],{"trials":4478,"activeCount":101},[],{"trials":4480,"activeCount":101},[],{"trials":4482,"activeCount":101},[],{"trials":4484,"activeCount":101},[],{"trials":4486,"activeCount":101},[4487],{"nctId":4488,"briefTitle":4489,"status":324,"phases":4490,"primaryCompletion":4491,"completion":4491,"start":4492,"enrollment":522,"conditions":4493,"interventions":4495},"NCT05775952","Airway Remodeling and Rhinovirus in Asthmatics",[],"2024-12-31","2011-09-01",[33,4494],"Respiratory Disease",[4473],{"intervention":4497,"totalTrials":97,"cells":4498},"Engerix-B",{"EARLY_PHASE1":4499,"PHASE1":4501,"PHASE2":4503,"PHASE3":4505,"PHASE4":4507,"NA":4509},{"trials":4500,"activeCount":101},[],{"trials":4502,"activeCount":101},[],{"trials":4504,"activeCount":101},[],{"trials":4506,"activeCount":101},[],{"trials":4508,"activeCount":101},[],{"trials":4510,"activeCount":101},[4511],{"nctId":4512,"briefTitle":4513,"status":337,"phases":4514,"primaryCompletion":2241,"completion":2241,"start":3791,"enrollment":388,"conditions":4515,"interventions":4519},"NCT02985450","A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada",[],[4516,4517,4518],"Non-Alcoholic Fatty Liver Disease","Hepatitis B","Vaccine Reaction",[4497],{"intervention":4521,"totalTrials":97,"cells":4522},"Vaginal progesterone gel",{"EARLY_PHASE1":4523,"PHASE1":4525,"PHASE2":4527,"PHASE3":4529,"PHASE4":4531,"NA":4533},{"trials":4524,"activeCount":101},[],{"trials":4526,"activeCount":101},[],{"trials":4528,"activeCount":101},[],{"trials":4530,"activeCount":101},[],{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":101},[4535],{"nctId":4536,"briefTitle":4537,"status":337,"phases":4538,"primaryCompletion":4539,"completion":4539,"start":4540,"enrollment":4541,"conditions":4542,"interventions":4544},"NCT00343265","Vaginal Progesterone Versus Placebo in Multiple Pregnancy",[93],"2011-03","2006-06",84,[4543],"Preterm Birth",[4521],{"intervention":4546,"totalTrials":97,"cells":4547},"Post-op Oral Steroids",{"EARLY_PHASE1":4548,"PHASE1":4550,"PHASE2":4552,"PHASE3":4554,"PHASE4":4556,"NA":4558},{"trials":4549,"activeCount":101},[],{"trials":4551,"activeCount":101},[],{"trials":4553,"activeCount":101},[],{"trials":4555,"activeCount":101},[],{"trials":4557,"activeCount":101},[],{"trials":4559,"activeCount":101},[4560],{"nctId":4561,"briefTitle":4562,"status":337,"phases":4563,"primaryCompletion":4564,"completion":4565,"start":2404,"enrollment":286,"conditions":4566,"interventions":4572},"NCT01564355","Postoperative Systemic Corticosteroids When Utilizing a Steroid-Eluting Spacer Following Endoscopic Sinus Surgery",[93],"2013-09","2013-12",[4567,4568,4569,4570,4571],"Chronic Sinusitis","Endoscopic Sinus Surgery","Post-operative Care","Steroids","Drug-eluting Spacer",[4546],{"intervention":4574,"totalTrials":97,"cells":4575},"Prehab",{"EARLY_PHASE1":4576,"PHASE1":4578,"PHASE2":4580,"PHASE3":4582,"PHASE4":4584,"NA":4586},{"trials":4577,"activeCount":101},[],{"trials":4579,"activeCount":101},[],{"trials":4581,"activeCount":101},[],{"trials":4583,"activeCount":101},[],{"trials":4585,"activeCount":101},[],{"trials":4587,"activeCount":101},[4588],{"nctId":4589,"briefTitle":4590,"status":337,"phases":4591,"primaryCompletion":4592,"completion":4462,"start":4593,"enrollment":4594,"conditions":4595,"interventions":4599},"NCT04247776","Pragmatic Prehabilitation for Colorectal Surgery",[93],"2020-09-01","2018-12-01",110,[4596,4597,4598],"Prehabilitation","Colorectal Surgery","Enhanced Recovery After Surgery",[4574],{"intervention":4601,"totalTrials":97,"cells":4602},"Avaxim Pediatric®",{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4607,"PHASE3":4609,"PHASE4":4611,"NA":4613},{"trials":4604,"activeCount":101},[],{"trials":4606,"activeCount":101},[],{"trials":4608,"activeCount":101},[],{"trials":4610,"activeCount":101},[],{"trials":4612,"activeCount":101},[],{"trials":4614,"activeCount":101},[4615],{"nctId":4616,"briefTitle":4617,"status":337,"phases":4618,"primaryCompletion":2846,"completion":2846,"start":4619,"enrollment":4620,"conditions":4621,"interventions":4623},"NCT02917577","Hepatitis A Vaccine Dosing Regimens Among Pediatric Patients on Immunosuppressive Therapy",[93],"2016-11-22",19,[4622],"Autoimmune Rheumatologic Disease",[4601,4624],"Avaxim ®",{"intervention":4624,"totalTrials":97,"cells":4626},{"EARLY_PHASE1":4627,"PHASE1":4629,"PHASE2":4631,"PHASE3":4633,"PHASE4":4635,"NA":4637},{"trials":4628,"activeCount":101},[],{"trials":4630,"activeCount":101},[],{"trials":4632,"activeCount":101},[],{"trials":4634,"activeCount":101},[],{"trials":4636,"activeCount":101},[],{"trials":4638,"activeCount":101},[4639],{"nctId":4616,"briefTitle":4617,"status":337,"phases":4640,"primaryCompletion":2846,"completion":2846,"start":4619,"enrollment":4620,"conditions":4641,"interventions":4642},[93],[4622],[4601,4624],{"intervention":4644,"totalTrials":97,"cells":4645},"Standard Treatment during painful bedside procedure",{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4650,"PHASE3":4652,"PHASE4":4654,"NA":4656},{"trials":4647,"activeCount":101},[],{"trials":4649,"activeCount":101},[],{"trials":4651,"activeCount":101},[],{"trials":4653,"activeCount":101},[],{"trials":4655,"activeCount":101},[],{"trials":4657,"activeCount":101},[4658],{"nctId":4659,"briefTitle":4660,"status":324,"phases":4661,"primaryCompletion":4662,"completion":4662,"start":4663,"enrollment":1080,"conditions":4664,"interventions":4665},"NCT04218396","Virtual Reality Use for Peri-Procedural Analgesia and Anxiolysis",[93],"2021-01-20","2020-01-30",[356],[4644],{"intervention":4667,"totalTrials":97,"cells":4668},"Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).",{"EARLY_PHASE1":4669,"PHASE1":4671,"PHASE2":4673,"PHASE3":4675,"PHASE4":4677,"NA":4679},{"trials":4670,"activeCount":101},[],{"trials":4672,"activeCount":101},[],{"trials":4674,"activeCount":101},[],{"trials":4676,"activeCount":101},[],{"trials":4678,"activeCount":101},[],{"trials":4680,"activeCount":101},[4681],{"nctId":4682,"briefTitle":4683,"status":337,"phases":4684,"primaryCompletion":4685,"completion":4685,"start":4686,"enrollment":4687,"conditions":4688,"interventions":4690},"NCT05037617","The REDUCED-I Pilot Trial: REDucing the Utilization of CEsarean Sections With Induction",[93],"2024-02-15","2021-10-25",205,[4689],"Induced; Birth",[4667],{"intervention":4692,"totalTrials":97,"cells":4693},"Polyethylene Glycol",{"EARLY_PHASE1":4694,"PHASE1":4696,"PHASE2":4698,"PHASE3":4700,"PHASE4":4702,"NA":4704},{"trials":4695,"activeCount":101},[],{"trials":4697,"activeCount":101},[],{"trials":4699,"activeCount":101},[],{"trials":4701,"activeCount":101},[],{"trials":4703,"activeCount":101},[],{"trials":4705,"activeCount":101},[4706],{"nctId":4707,"briefTitle":4708,"status":337,"phases":4709,"primaryCompletion":4710,"completion":4710,"start":4711,"enrollment":1255,"conditions":4712,"interventions":4714},"NCT01610856","Single Dose Versus Split Dose Polyethylene Glycol-based Colonic Lavage for Colonoscopy",[93],"2010-06","2010-03",[4713],"Colonoscopy Preparation",[4692,4715],"polyethylene glycol",{"intervention":4717,"totalTrials":97,"cells":4718},"FloraBaby",{"EARLY_PHASE1":4719,"PHASE1":4721,"PHASE2":4723,"PHASE3":4725,"PHASE4":4727,"NA":4729},{"trials":4720,"activeCount":101},[],{"trials":4722,"activeCount":101},[],{"trials":4724,"activeCount":101},[],{"trials":4726,"activeCount":101},[],{"trials":4728,"activeCount":101},[],{"trials":4730,"activeCount":101},[4731],{"nctId":4732,"briefTitle":4733,"status":892,"phases":4734,"primaryCompletion":4735,"completion":4735,"start":4736,"enrollment":465,"conditions":4737,"interventions":4742},"NCT03266315","Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery",[93],"2024-07-15","2022-12-03",[4738,4739,4740,4741],"Probiotics","Infant, Newborn","Surgical Procedures, Operative","Gastro-Intestinal Disorder",[4717],{"intervention":4744,"totalTrials":97,"cells":4745},"Early auto-mode",{"EARLY_PHASE1":4746,"PHASE1":4748,"PHASE2":4750,"PHASE3":4752,"PHASE4":4754,"NA":4756},{"trials":4747,"activeCount":101},[],{"trials":4749,"activeCount":101},[],{"trials":4751,"activeCount":101},[],{"trials":4753,"activeCount":101},[],{"trials":4755,"activeCount":101},[],{"trials":4757,"activeCount":101},[4758],{"nctId":4759,"briefTitle":4760,"status":337,"phases":4761,"primaryCompletion":4762,"completion":4762,"start":4763,"enrollment":1040,"conditions":4764,"interventions":4769},"NCT04420728","Closed-Loop Insulin in Mothers With Type 1 Diabetes and Baby Feeding Practices",[93],"2023-02-28","2020-07-15",[4765,4766,4767,4768],"Diabetes Mellitus Type 1 Pre-Existing","Pregnancy Related","Feeding Behavior","Infant Development",[4744,4770],"Delayed auto mode",{"intervention":4770,"totalTrials":97,"cells":4772},{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4777,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4774,"activeCount":101},[],{"trials":4776,"activeCount":101},[],{"trials":4778,"activeCount":101},[],{"trials":4780,"activeCount":101},[],{"trials":4782,"activeCount":101},[],{"trials":4784,"activeCount":101},[4785],{"nctId":4759,"briefTitle":4760,"status":337,"phases":4786,"primaryCompletion":4762,"completion":4762,"start":4763,"enrollment":1040,"conditions":4787,"interventions":4788},[93],[4765,4766,4767,4768],[4744,4770],{"intervention":4790,"totalTrials":97,"cells":4791},"Tranexamic acid",{"EARLY_PHASE1":4792,"PHASE1":4794,"PHASE2":4796,"PHASE3":4798,"PHASE4":4800,"NA":4802},{"trials":4793,"activeCount":101},[],{"trials":4795,"activeCount":101},[],{"trials":4797,"activeCount":101},[],{"trials":4799,"activeCount":101},[],{"trials":4801,"activeCount":101},[],{"trials":4803,"activeCount":101},[4804],{"nctId":4805,"briefTitle":4806,"status":1493,"phases":4807,"primaryCompletion":4808,"completion":2476,"start":2337,"enrollment":4809,"conditions":4810,"interventions":4811},"NCT00671281","The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery",[93],"2009-06",74,[4567],[4790],{"intervention":4813,"totalTrials":97,"cells":4814},"Control intervention",{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4819,"PHASE3":4821,"PHASE4":4823,"NA":4825},{"trials":4816,"activeCount":101},[],{"trials":4818,"activeCount":101},[],{"trials":4820,"activeCount":101},[],{"trials":4822,"activeCount":101},[],{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":101},[4827],{"nctId":4828,"briefTitle":4829,"status":324,"phases":4830,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":4834,"conditions":4835,"interventions":4840},"NCT02666443","Low Dose Dexamethasone in Supraclavicular Blocks",[93],"2020-02","2021-02","2016-09",306,[4836,4837,4838,4839],"Rheumatoid Arthritis","Osteoarthritis","Nerve Entrapment","Ligament Injury",[4813,4841,4842],"Peri-neural Dexamethasone 1 mg","Intravenous Dexamethasone 1 mg",{"intervention":4841,"totalTrials":97,"cells":4844},{"EARLY_PHASE1":4845,"PHASE1":4847,"PHASE2":4849,"PHASE3":4851,"PHASE4":4853,"NA":4855},{"trials":4846,"activeCount":101},[],{"trials":4848,"activeCount":101},[],{"trials":4850,"activeCount":101},[],{"trials":4852,"activeCount":101},[],{"trials":4854,"activeCount":101},[],{"trials":4856,"activeCount":101},[4857],{"nctId":4828,"briefTitle":4829,"status":324,"phases":4858,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":4834,"conditions":4859,"interventions":4860},[93],[4836,4837,4838,4839],[4813,4841,4842],{"intervention":4842,"totalTrials":97,"cells":4862},{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4867,"PHASE3":4869,"PHASE4":4871,"NA":4873},{"trials":4864,"activeCount":101},[],{"trials":4866,"activeCount":101},[],{"trials":4868,"activeCount":101},[],{"trials":4870,"activeCount":101},[],{"trials":4872,"activeCount":101},[],{"trials":4874,"activeCount":101},[4875],{"nctId":4828,"briefTitle":4829,"status":324,"phases":4876,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":4834,"conditions":4877,"interventions":4878},[93],[4836,4837,4838,4839],[4813,4841,4842],{"intervention":4880,"totalTrials":97,"cells":4881},"inactivated seasonal flu vaccine",{"EARLY_PHASE1":4882,"PHASE1":4884,"PHASE2":4886,"PHASE3":4888,"PHASE4":4890,"NA":4892},{"trials":4883,"activeCount":101},[],{"trials":4885,"activeCount":101},[],{"trials":4887,"activeCount":101},[],{"trials":4889,"activeCount":101},[],{"trials":4891,"activeCount":101},[],{"trials":4893,"activeCount":101},[4894],{"nctId":4895,"briefTitle":4896,"status":337,"phases":4897,"primaryCompletion":4898,"completion":4899,"start":4900,"enrollment":2312,"conditions":4901,"interventions":4903},"NCT02451332","Prenatal Inflammation and Perinatal Outcomes",[93],"2019-12","2020-08","2015-10",[4902],"Pregnancy",[4880],{"intervention":4905,"totalTrials":97,"cells":4906},"Detemir",{"EARLY_PHASE1":4907,"PHASE1":4909,"PHASE2":4911,"PHASE3":4913,"PHASE4":4915,"NA":4917},{"trials":4908,"activeCount":101},[],{"trials":4910,"activeCount":101},[],{"trials":4912,"activeCount":101},[],{"trials":4914,"activeCount":101},[],{"trials":4916,"activeCount":101},[],{"trials":4918,"activeCount":101},[4919],{"nctId":4920,"briefTitle":4921,"status":337,"phases":4922,"primaryCompletion":4539,"completion":4539,"start":4923,"enrollment":16,"conditions":4924,"interventions":4926},"NCT00522210","Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes",[93],"2008-03",[4925],"Type 1 Diabetes",[4905],{"intervention":4928,"totalTrials":97,"cells":4929},"Influenza vaccination",{"EARLY_PHASE1":4930,"PHASE1":4932,"PHASE2":4934,"PHASE3":4936,"PHASE4":4938,"NA":4940},{"trials":4931,"activeCount":101},[],{"trials":4933,"activeCount":101},[],{"trials":4935,"activeCount":101},[],{"trials":4937,"activeCount":101},[],{"trials":4939,"activeCount":101},[],{"trials":4941,"activeCount":101},[4942],{"nctId":4943,"briefTitle":4944,"status":337,"phases":4945,"primaryCompletion":4946,"completion":4947,"start":4948,"enrollment":4949,"conditions":4950,"interventions":4952},"NCT01666535","Infliximab IBD Influenza Vaccine Study",[93],"2013-03","2013-08","2012-09",137,[4951],"Inflammatory Bowel Disease",[4928]]